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A B S T R A C T
Background
Cancer increases the risk of thromboembolic events in patients including those receiving anticoagulation treatments.
Objectives
To compare the efficacy and safety of low molecular weight heparin (LMWH) and oral anticoagulants for the long-term treatment of
venous thromboembolism (VTE) in patients with cancer.
Search methods
We conducted a comprehensive search for studies of anticoagulation in cancer patients including 1. a February 2013 electronic search
of: the Cochrane Central Register of Controlled Trials (CENTRAL Issue 12, 2012), MEDLINE, and EMBASE; 2. a handsearch of
conference proceedings; 3. checking of references of included studies; 4. use of the ’related citation’ feature in PubMed; and 5. a search
of clinicaltrials.gov for ongoing studies.
Selection criteria
We included randomized controlled trials (RCTs) comparing long-term treatment with LMWH versus oral anticoagulants (vitamin K
antagonist (VKA) or ximelagatran) in patients with cancer and symptomatic objectively confirmed VTE.
Data collection and analysis
Using a standardized data form, we extracted data on methodological quality, participants, interventions and outcomes of interest:
survival, recurrent VTE, major bleeding, minor bleeding, thrombocytopenia, and postphlebitic syndrome. We assessed the quality of
evidence at the outcome level following the GRADE approach.
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Main results
Of 9559 identified citations, 10 RCTs (11 reports) were eligible and reported data for 1981 patients with cancer. We excluded 14
studies in which patients with cancer constituted study subgroups, but did not report outcome data for them. Meta-analysis of seven
RCTs comparing LMWHwith VKA found no statistically significant survival benefit (hazard ratio (HR) 0.96; 95% confidence interval
(CI) 0.81 to 1.14) but a statistically significant reduction in VTE (HR 0.47; 95% CI 0.32 to 0.71). The remaining findings did not
exclude a beneficial or harmful effect of LMWH compared with VKA for the outcomes of major bleeding (RR 1.07; 95% CI 0.52 to
2.19), minor bleeding (RR 0.89; 95% CI 0.51 to 1.55), or thrombocytopenia (RR 0.98; 95% CI 0.57 to 1.66). We judged the quality
of evidence as low for mortality, major bleeding, and minor bleeding, and as moderate for recurrent VTE.
OneRCTcomparingdabigatranwithVKAdidnot exclude beneficial or harmful effects of one agent over the other.OneRCTcomparing
six months’ extension of anticoagulation with 18 months of ximelagatran 24 mg twice daily versus no extended ximelagatran did not
exclude beneficial or harmful effects for the outcomes of reduction in VTE, mortality, and minor bleeding. One RCT comparing once-
weekly subcutaneous injection of idraparinux for three or six months versus standard treatment (parenteral anticoagulation followed
by warfarin or acenocoumarol) suggested a reduction in recurrent VTE (HR 0.39; 95% CI 0.14 to 1.11) at six months, but did not
exclude beneficial or harmful effects for the outcomes of mortality (HR 0.99; 95% CI 0.66 to 1.48) and major bleeding (RR 1.04;
95% CI 0.39 to 2.83).
Authors’ conclusions
For the long-term treatment of VTE in patients with cancer, LMWH compared with VKA reduces venous thromboembolic events but
not mortality. The decision for a patient with cancer and VTE to start long-term LMWH versus oral anticoagulation should balance
the benefits and harms and integrate the patient’s values and preferences for the important outcomes and alternative management
strategies.
P L A I N L A N G U A G E S U M M A R Y
Blood thinners for the long-term treatment of blood clots in patients with cancer
Background
Patients with cancer are at an increased risk of developing blood clots and might respond differently to blood thinners (anticoagulants)
compared with patients without cancer.
Study characteristics
We searched scientific databases for clinical trials looking at the effects of long-term treatment with different blood thinners on blood
clot recurrence in people with cancer with a confirmed diagnosis of deep venous thrombosis (a blood clot in the legs) or pulmonary
thrombosis (a blood clot in the lungs). We included trials of adults and children with either solid tumors or blood cancer irrespective
of the type of cancer treatment. The trials looked at survival, recurrent blood clot, bleeding, blood platelet levels (which are involved
in blood clotting), and postphlebitic syndrome (a complication of long-term blood clots). The evidence is current to February 2013.
Key results
We found 10 studies with 1981 patients with cancer. The studies found that low molecular weight heparins (injectable blood thinners)
were superior to vitamin K antagonists (oral blood thinners) in reducing the recurrence of blood clots. The available data suggested
that both drugs have equal effects on death and the side effect of bleeding.
Quality of the evidence
We were unable to include several possibly relevant studies because the required data were not available. We judged the quality of the
evidence for recurrence of blood clots as moderate and the quality of the evidence as low for death and bleeding.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Low molecular weight heparin compared with vitamin K antagonist for patients with cancer requiring long- term anticoagulation for venous thromboembolism
Patient or population: pat ients with cancer requiring long-term anticoagulat ion for VTE
Settings: outpat ient
Intervention: LMWH
Comparison: VKA
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
VKA LMWH
Mortality
Follow-up: 3-6 months
(at any point)
399 per 1000 383 per 1000
(323 to 451)
RR 0.96
(0.81 to 1.13)
897
(3 studies)
⊕⊕©©
low1,2
-
Recurrent VTE
Follow-up: 3-6 months
140 per 1000 71 per 1000
(49 to 106)
RR 0.51
(0.35 to 0.76)
964
(4 studies)
⊕⊕⊕©
moderate2
-
Major bleeding
Follow-up: 3-6 months
60 per 1000 64 per 1000
(31 to 131)
RR 1.07
(0.52 to 2.19)
1092
(4 studies)
⊕⊕©©
low1,2
-
Minor bleeding
Follow-up: 3-6 months
176 per 1000 156 per 1000
(90 to 272)
RR 0.89
(0.51 to 1.55)
1091
(4 studies)
⊕⊕©©
low2
-
Postphlebitic syn-
drome - not reported
- - Not est imable - - Not reported
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; LMWH: low molecular weight heparin; RR: risk rat io; VKA: vitamin K antagonist ; VTE: venous thromboembolism.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 CI includes values suggest ing both no ef fect and values suggest ing either benef it or harm.
2 We could not obtain data for subgroups of pat ients with cancer in 11 RCTs.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Table 1 lists a glossary of terms.
Description of the condition
The presence of cancer increases the risk of venous thromboem-
bolism (VTE) four- to six-fold (Heit 2000). Cancer-related inter-
ventions such as chemotherapy, hormonal therapy, and indwelling
central venous catheters also increase the risk of VTE (Heit 2000).
Similarly, patients undergoing surgery for cancer have a higher
risk of VTE than patients undergoing surgery for benign diseases
(Gallus 1997; Kakkar 1970). Furthermore, patients with cancer
and VTE have a higher risk of death than patients with cancer
alone or with VTE alone (Levitan 1999; Sorensen 2000).
Patients with cancer also have different benefits and risks from an-
ticoagulant treatment than patients without cancer. For instance,
during oral anticoagulation therapy for VTE, patients with cancer,
compared with patients without cancer, have a higher incidence
of recurrent VTE (27.1 versus 9.0 events per 100 patient-years, P
value = 0.003) and of major bleeding (13.3 versus 2.2 events per
100 patient-years, P value = 0.002) (Hutten 2000).
Description of the intervention
Low molecular weight heparins (LMWHs) do not have intrinsic
anticoagulant activity but potentiate the activity of antithrombin
III in inhibiting activated coagulation factors. These agents consti-
tute indirect anticoagulants as their activity is mediated by plasma
cofactors. LMWHs are not absorbed orally and must be adminis-
tered parenterally by subcutaneous injections (Hirsh 1993).
Vitamin K antagonists (VKA) have been the mainstay of oral an-
ticoagulant therapy since the 1950s. Well-designed clinical trials
have shown the effectiveness of VKAs for the primary and sec-
ondary prevention of several venous and arterial thrombotic dis-
eases (Ansell 2008).
How the intervention might work
Several systematic reviews have compared LMWH and VKA in
the long-term treatment of VTE, but in populations not restricted
to patients with cancer (Conti 2003; Iorio 2003; van der Heijden
2007). The review by van der Heijden et al. did not complete a
preplanned subgroup analysis in patients with cancer as the re-
quired data were not specifically reported (van der Heijden 2007).
The review by Conti et al. did not conduct a meta-analysis in the
subgroup of patients with cancer (Conti 2003). In the review by
Iorio et al., one meta-analysis in the subgroup of patients with can-
cer found no statistically significant difference in mortality (OR
1.13; 95% CI 0.54 to 2.38).
Why it is important to do this review
The subgroup analysis in Iorio 2003 did not report on the com-
parative safety of LMWH and VKA (Iorio 2003). The Cochrane
Collaboration has recognized that addressing all important out-
comes including harm is of great importance to make evidence-
based healthcare decisions. The last update of this Cochrane sys-
tematic review concluded that the existing evidence suggested a
reduction in venous thromboembolic events in patients with can-
cer but not mortality (Akl 2011). Since 2011, there have been
publications of studies assessing the newer oral anticoagulants, so
we aimed to update this systematic review to capture and include
any such studies relevant to our question.
O B J E C T I V E S
To compare the efficacy and safety of LMWH and oral anticoagu-
lants for the long-term treatment of VTE in patients with cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs).
Types of participants
Patients with cancer with a confirmed diagnosis of VTE (deep ve-
nous thrombosis (DVT) or pulmonary embolism (PE)). Patients
could have been of any age group (including children), with ei-
ther solid or hematologic cancer, at any stage of their cancer, and
irrespective of the type of cancer therapy.
DVT should have been diagnosed using one the following ob-
jective diagnostic tests: venography, 125I-fibrinogen-uptake test,
impedance plethysmography, or Doppler-ultrasound. PE should
have been diagnosed using one of the following objective diag-
nostic tests: pulmonary perfusion/ventilation scans, computed to-
mography, or pulmonary angiography).
Types of interventions
We included studies comparing long-term treatmentwith LMWH
versus oral anticoagulants (VKA or ximelagatran). There should
have been no differences in how the study groups were treated
besides the main intervention (e.g. the type of initial anticoagula-
tion), that is, studies should have treated patient groups similarly
apart from the intervention of interest.
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Types of outcome measures
Primary outcomes
• Survival.
Secondary outcomes
• Symptomatic recurrent DVT.
• Symptomatic recurrent PE.
• Major bleeding.
• Minor bleeding.
• Thrombocytopenia.
• Postphlebitic syndrome.
We accepted the definitions of major bleeding, minor bleeding,
thrombocytopenia, and postphlebitic syndrome of the authors of
the original studies as long as they were standardized.
Search methods for identification of studies
Electronic searches
The search was part of a comprehensive search for studies of an-
ticoagulation in patients with cancer. We conducted the origi-
nal electronic search in January 2007 and updated it in Febru-
ary 2010 and in February 2013. We electronically searched the
following databases: the Cochrane Central Register of Controlled
Trials (CENTRAL) (Issue 12, 2012), MEDLINE (1966 onward;
accessed via Ovid), EMBASE (1980 onward; accessed via Ovid),
and ISI Web of Science (February 2010). The search strategies
combined terms relating to the anticoagulants, cancer, and study
design. We list the search strategies in Appendix 1 and Appendix
2.
Searching other resources
In addition to the electronic search, we used a number of supple-
mental search strategies.Wehandsearched the conference proceed-
ings of the American Society of Clinical Oncology (ASCO, start-
ing with its first volume, 1982 up to June 2013) and of the Ameri-
can Society ofHematology (ASH, startingwith its 2003 issue up to
June 2013). We reviewed the reference lists of included papers, rel-
evant papers, and related systematic reviews (Conti 2003; van der
Heijden 2007).We used the ’related citation’ feature in PubMed to
identify additional papers. We used ISIWeb of Science to identify
papers citing the landmark studies. We used no language restric-
tions. We also searched ClinicalTrials.gov (clinicaltrials.gov/) for
ongoing studies.
Data collection and analysis
Selection of studies
Two review authors independently screened the title and abstract
of identified article citations for potential eligibility. We retrieved
the full text of articles judged potentially eligible by at least one
review author. Two review authors then independently screened
the full-text article for eligibility using a standardized form with
explicit inclusion and exclusion criteria (as detailed in the Criteria
for considering studies for this review section). We resolved any
disagreements about which articles were eligible by discussion or
by consulting a third review author.
Data extraction and management
For English articles, two review authors independently extracted
the data from each study and resolved their disagreements by dis-
cussion or by consulting a third review author. For non-English
articles, one review author extracted data. The collected data re-
lated to the following.
Participants
• Demographic characteristics (e.g. age, sex).
• Cancer characteristics (e.g. histologic type, site of origin,
stage, time since diagnosis, estimated life expectancy, current
cancer treatments, performance status).
• Whether participants had DVT, PE, or both.
• Number of patients in each treatment arm.
Interventions
• Type and dosage schedule of LMWH.
• Intensity of VKA.
• Dosage schedule of ximelagatran.
• Type (unfractionated heparin (UFH) versus LMWH versus
fondaparinux) and duration of initial anticoagulation.
• Co-interventions including radiation therapy,
chemotherapy, and hormonal therapy (type and duration).
Outcomes
We extracted both time-to-event data and binary data.
For time-to-event data, we abstracted the log (hazard ratio (HR))
and its variance from trial reports; if these were not reported,
we digitized the published Kaplan-Meier survival curves and esti-
mated the log(HR) and its variance using the method of Parmar
(Parmar 1998). We also noted the minimum and maximum dura-
tion of follow-up, which are required to make these estimates. We
performed these calculations in Stata 9, using a specially written
program, which yielded the reported log(HR) and variance when
used on the data presented in Table V of Parmar 1998.
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For binary data, we extracted the reported outcome data necessary
to conduct intention-to-treat (ITT) analyses. We collected out-
come event rates whenever they were reported in each trial. When
the authors did not report and could not provide the number of
events at specific time points, two biostatisticians estimated these
numbers independently and in duplicate from survival curves, if
available.
We attempted to contact authors for incompletely reported data.
We decided a priori to consider abstracts only if authors supplied
us with full reports of their methods and results.
Assessment of risk of bias in included studies
We assessed risk of bias at the study level using The Cochrane
Collaboration’s ’Risk of bias’ tool. Two review authors indepen-
dently assessed the methodologic quality of each included study
and resolved any disagreements by discussion. Methodologic cri-
teria included the following:
• adequate sequence generation;
• allocation concealment;
• patient blinding;
• provider blinding;
• data collector blinding;
• outcome assessor blinding;
• analyst blinding;
• percentage followed up and whether incomplete outcome
data were addressed;
• whether the study was free of selective outcome reporting;
• whether the study was stopped early for benefit;
• whether the analysis followed the ITT principle.
See section on Dealing with missing data about assessing risk of
bias associated with participants with missing data.
Measures of treatment effect
We collected and analyzed HRs for time-to-event data and risk
ratios (RRs) for dichotomous data. None of the outcomes of in-
terest was meta-analyzed as a continuous variable.
Unit of analysis issues
The unit of analysis was the individual participant.
Dealing with missing data
Determining participants with missing data
It was not clear whether certain participant categories (e.g. those
described as ’withdrew consent’ or ’experienced adverse events’)
were actually followed up by the trialists (versus had missing par-
ticipant data). To deal with this issue, we made the following con-
siderations:
• ’ineligible participants’, and ’did not receive the first dose’
participant categories, which were defined prior to the initiation
of the study intervention, most likely had missing participant
data;
• ’withdrew consent’ and ’lost to follow-up’ participant
categories, which were defined after the initiation of the study
intervention, most likely had missing participant data;
• ’dead’, ’experienced adverse events’, ’non-compliant’,
’discontinued prematurely’ (and similarly described) participant
categories, less likely had missing participant data.
Dealing with participants with missing data in the primary
meta-analysis
In the primary meta-analysis, we used a complete case analysis
approach, that is, we excluded participants considered to have
missing data.
For categorical data, we used the following calculations for each
study arm:
• denominator: (number of participants randomized) -
(number of participants most likely with missing data, both pre-
and post-intervention initiation);
• numerator: number of participants with observed events
(i.e. participants who suffered at least one event for the outcome
of interest during their available follow-up time).
For continuous data, we used for each study arm, the reported
mean and standard deviation (SD) for participants actually fol-
lowed up by the trialists.
Assessing the risk of bias associated with participants with
missing data
When the primary meta-analysis of a specific outcome found a
statistically significant effect, we conducted sensitivity meta-anal-
yses to assess the risk of bias associated with missing participant
data. Those sensitivity meta-analyses used a priori plausible as-
sumptions about the outcomes of participants considered to have
missing data. The assumptions we used in the sensitivity meta-
analyses were increasingly stringent in order to challenge the sta-
tistical significance of the results of the primary analysis progres-
sively (Akl 2013; Ebrahim 2013).
For categorical data and for RR showing a reduction in effect
(RR less than 1), we used the following increasingly stringent but
plausible assumptions (Akl 2013):
• for the control arm, relative incidence (RI) among those
with missing data (lost to follow-up (LTFU)) compared with
those with available data (followed up, FU) in the same arm
(RILT FU/FU ) = 1; for the intervention arm, RILT FU/FU = 1.5;
• for the control arm, RILT FU/FU = 1; for the intervention
arm, RILT FU/FU = 2;
• for the control arm, RILT FU/FU = 1; for the intervention
arm, RILT FU/FU = 3;
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• for the control arm, RILT FU/FU = 1; for the intervention
arm, RILT FU/FU = 5.
For RR showing an increase in effect (RR greater than 1), we
switched the above assumptions between the control and inter-
ventions arms (i.e. used RILT FU/FU = 1 for the intervention arm).
Specifically, we used the following calculations for each study arm:
• denominator: (number of participants randomized) -
(number of participants most likely with missing data,
preintervention initiation);
• numerator: (number of participants with observed events) +
(number of participants most likely with missing data post-
intervention initiation, with assumed events).
Assumed events are calculated by applying the a priori plausible
assumptions to the participants considered most likely with miss-
ing data post-intervention initiation.
For continuous data, we used the four strategies suggested by
Ebrahim et al. (Ebrahim 2013). The strategies imputed the means
for participants with missing data based on the means of partici-
pants actually followed up in individual trials included in the sys-
tematic review. To impute SD, we used the median SD from the
control arms of all included trials. (Ebrahim 2013.)
Assessment of heterogeneity
We assessed heterogeneity between trials by visual inspection of
forest plots, estimation of the percentage heterogeneity between
trials that cannot be ascribed to sampling variation (I2 statistic)
(Higgins 2011), and by a formal statistical test of the significance
of the heterogeneity. If there was evidence of substantial hetero-
geneity, we investigated and reported the possible reasons for this.
Assessment of reporting biases
We assessed reporting bias by trying to identify whether the study
was included in a trial registry, whether a protocol was available,
and whether the methods section provided a list of outcomes (to
assess selective outcome reporting bias). We compared the list of
outcomes from those sources to the outcomes reported in the
published paper.
We created inverted funnel plots of individual study results plotted
against sample size in order to evaluate possible publication bias.
Data synthesis
We calculated the agreement between the two independent review
authors for the assessment of eligibility using the kappa statistic.
We analyzed, when possible, both time-to-event data and binary
data.
For time-to-event data, we pooled the log(HR) values using a
random-effects model and the generic inverse variance facility of
Review Manager 5 (RevMan 2012).
For binary data, for a specific outcome, and for each trial, we used
the ITT principle to calculate the RR separately for each study.
We then pooled the results of the different studies using a random-
effects model.
We assessed the quality of evidence at the outcome level using
the Grading of Recommendations Assessment, Development and
Evaluation (GRADE) approach (Higgins 2011).
Subgroup analysis and investigation of heterogeneity
We evaluated heterogeneity across trials using the I2 statistic, based
on the following classification with the value of I2: 0 to 30 = low;
30 to 60 = moderate and worthy of investigation; 60 to 90 =
severe and worthy of understanding; and 90 to 100 = allowing
aggregation only with major caution.
Sensitivity analysis
We conducted sensitivity analysis by excluding the study of lowest
methodologic quality (Cesarone 2003), and then a study that used
a different initial anticoagulant in the two study arms (post hoc
analysis) (Hull 2006).
In addition, when the primary meta-analysis of a specific outcome
found a statistically significant effect, we conducted sensitivity
meta-analyses to assess the risk of bias associated with missing
participant data.
R E S U L T S
Description of studies
Results of the search
The February 2013 search strategy identified 9559 citations (after
removal of duplicates) from which we removed the results of our
January 2010 search. The title and abstract screening of the 9559
unique citations identified 65 as potentially eligible for this review.
We included 10 studies (11 reports) and excluded the remaining
54 studies. Figure 1 shows the study flow diagram. Agreement
between authors for study eligibility was excellent (kappa = 0.94).
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Figure 1. Study flow diagram.
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Included studies
We included 10 RCTs (11 reports) with 1981 patients with can-
cer for which outcome data were available (see Characteristics
of included studies table). Nine studies were published in full
text (Deitcher 2006; Hull 2006; Lee 2003; Lopez-Beret 2001;
Meyer 2002; Schulman 2003; Schulman 2009; Romera 2009; van
Doormaal 2010), and one was published as an abstract (Cesarone
2003). Seven RCTs compared a LMWHwith a VKA for the long-
term treatment of VTE (Cesarone 2003; Deitcher 2006; Hull
2006; Lee 2003; Lopez-Beret 2001; Meyer 2002; Romera 2009);
only one of these studies used a different initial anticoagulant in
the two study arms (LMWH in the LMWH group and UFH in
the VKA group) (Hull 2006). One study compared dabigatran
with warfarin for six months (Schulman 2009). One study with a
subgroup of patients with cancer compared 18months of extended
treatment with ximelagatran versus placebo, after six months of
anticoagulant therapy in patients with cancer (Schulman 2003).
OneRCTcompared a once-weekly subcutaneous injectionof idra-
parinux for three or six months versus standard treatment (tinza-
parin, enoxaparin, or dose-adjusted intravenous heparin followed
by warfarin or acenocoumarol).
Excluded studies
Of the 54 excluded studies, in 14 studies, patients with cancer con-
stituted study subgroups but their outcome data were not available
(Beckman 2003;Das 1996;Daskalopoulos 2005; Fiessinger 2005;
Gonzalez-Fajardo 1999; Hull 2007; Hull 2009; Kucher 2005;
Levine 1995; Lopaciuk 1999; Massicotte 2003; Pérez-de-Llano
2010; Pini 1994; Veiga 2000). We excluded the remaining 40
studies for the following reasons: case series (one study), review (15
studies), retrospective (four studies), protocol (two studies), ob-
servational (six studies), trial but not randomized and controlled
(four studies), no cancer patients included (four studies), only one
patient with cancer was included (one study), no relevant out-
come (two studies), and not intervention of interest (study com-
pared different duration of interventional drugs) (one study). See
Characteristics of excluded studies table.
Risk of bias in included studies
Figure 2 shows themethodologic quality graph and Figure 3 shows
the summary of the quality of the included studies. The method-
ologic quality varied by outcome. For the comparison of LMWH
with VKA, the quality of evidence was low for mortality, major
bleeding, and minor bleeding and moderate for recurrent VTE
(Summary of findings for the main comparison).
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Figure 2. Risk of bias graph: review authors’ judgments about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgments about each risk of bias item for each included
study.
12Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation
The concealment of allocation was adequate in seven trials (Hull
2006; Lee 2003; Meyer 2002; Romera 2009; Schulman 2003;
Schulman 2009; van Doormaal 2010), and unclear in the other
three (Cesarone 2003; Deitcher 2006; Lopez-Beret 2001).
Blinding
Three studies blinded patients (Romera 2009; Schulman 2003;
Schulman 2009), three studies blinded caregivers (Romera 2009;
Schulman 2003; Schulman 2009), three studies blinded data col-
lectors (Romera 2009; Schulman 2003; Schulman 2009), eight
studies blinded outcome adjudicators (Hull 2006; Lee 2003;
Lopez-Beret 2001;Meyer 2002; Schulman 2003; Schulman 2009;
Romera 2009; van Doormaal 2010), and five studies blinded data
analysts (Hull 2006; Lee 2003; Meyer 2002; Schulman 2003;
Schulman 2009).
Incomplete outcome data
The percentage follow-up ranged from 89% to 100%.
Selective reporting
We did not suspect selective reporting of outcomes for any of the
studies except for Cesarone 2003 as there was no report on the
bleeding events. The cancer subgroup data weremissing for a large
number of studies.
Other potential sources of bias
Eight studies conducted analysis consistent with the ITT principle
(Hull 2006; Lee 2003; Lopez-Beret 2001; Meyer 2002; Schulman
2003; Schulman 2009; Romera 2009; van Doormaal 2010). This
was not clear in two studies (Cesarone 2003; Deitcher 2006). One
study was stopped early for benefit (Meyer 2002).
Another potential source of bias is the screening for asymptomatic
VTE in three of the nine included studies (Lopez-Beret 2001;
Meyer 2002; Romera 2009).
Effects of interventions
See: Summary of findings for the main comparison Low
molecular weight heparin compared with vitamin K antagonist
for patients with cancer requiring long-term anticoagulation for
venous thromboembolism
Low molecular weight heparin versus vitamin K
antagonist
Survival
We used time-to-event data reported by two studies (Lee 2003;
Meyer 2002), and supplied by the author of a third study (Hull
2006). The pooled analysis showed no statistically significant sur-
vival benefit of LMWH over VKA (HR 0.96; 95% CI 0.81 to
1.14; I2 = 0%) (Analysis 1.1) (Figure 4).
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Figure 4. Funnel plot of comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist
(VKA), outcome: 1.1 Survival (time-to-event).
Three studies reported all-cause mortality at three months (
Cesarone 2003; Hull 2006;Meyer 2002). The pooled analysis did
not exclude clinically significant benefit or harm with LMWH
compared with VKA (RR 0.77; 95% CI 0.46 to 1.28; I2 = 17%)
(Analysis 1.2). The results were consistent in a sensitivity analysis
excluding the study published as an abstract (Cesarone 2003) (RR
0.76; 95% CI 0.37 to 1.55; I2 = 56%), and in a sensitivity analysis
excluding the study that used a different initial anticoagulant in
the two study arms (Hull 2006) (RR 0.51; 95% CI 0.25 to 1.04;
I2 = 0%).
Three studies reported all-cause mortality at six months (Deitcher
2006; Lee 2003; Meyer 2002). The pooled analysis showed no
statistically significant difference between LMWH and VKA (RR
0.96; 95% CI 0.81 to 1.13; I2 = 0%) (Analysis 1.3).
We finally pooled data from all studies irrespective of the timing
of outcome assessment and using the six-month data from the
study by Meyer et al. The pooled analysis showed no statistically
significant difference between LMWH and VKA (RR 0.97; 95%
CI 0.84 to 1.11; I2 = 0%) (Analysis 1.4). The results were consis-
tent in a sensitivity analysis excluding the study published as an
abstract (Cesarone 2003) (RR 0.97; 95% CI 0.85 to 1.10; I2 =
0%), and in a sensitivity analysis excluding the study that used a
different initial anticoagulant in the two study arms (Hull 2006)
(RR 0.97; 95% CI 0.84 to 1.11; I2 = 0%).
The inverted funnel plot for the outcome of all-cause mortality
did not suggest publication bias (Figure 5).
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Figure 5. Funnel plot of comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist
(VKA), outcome: 1.4 Mortality (at any time point).
Recurrent venous thromboembolism
We used time-to-event data reported by two studies (Lee 2003;
Meyer 2002), and supplied by the author of a third study (Hull
2006). The pooled analysis showed a statistically significant benefit
of LMWH over VKA (HR 0.47; 95% CI 0.32 to 0.71; I2 = 0%)
(Analysis 1.5) (Figure 6). The results were consistent in a binary
data analysis including five studies (RR0.50; 95%CI 0.35 to 0.71;
I2 = 0%) (Analysis 1.6) (Deitcher 2006; Hull 2006; Lee 2003;
Meyer 2002; Romera 2009), and a sensitivity analysis excluding
the study that used a different initial anticoagulant in the two
study arms (RR 0.51; 95% CI 0.35 to 0.76; I2 = 0%) (Hull 2006).
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Figure 6. Funnel plot of comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist
(VKA), outcome: 1.5 Recurrent venous thromboembolism (time-to-event).
Since the primary meta-analysis found a statistically significant
effect, and in order to assess the risk of bias associated with missing
participant data, we conducted sensitivity meta-analyses using the
a priori plausible assumptions detailed in themethods section. The
effect estimate remained statistically significant even when using
the most stringent plausible assumption (RR 0.53; 95% CI 0.38
to 0.75).
None of the studies reported DVT and PE as separate outcomes.
Bleeding outcomes
Four studies assessed bleeding outcomes (Deitcher 2006; Hull
2006; Lee 2003;Meyer 2002). The pooled analysis did not exclude
a beneficial or harmful effect of LMWH compared with VKA
for major bleeding (RR 1.07; 95% CI 0.52 to 2.19; I2 = 46%)
(Analysis 1.7) (Figure 7) or minor bleeding (RR 0.89; 95% CI
0.51 to 1.55; I2 = 77%) (Analysis 1.8) (Figure 8). The results
were consistent in a sensitivity analysis excluding the study that
used a different initial anticoagulant in the two study arms for the
outcomes of minor bleeding (RR 0.80; 95% CI 0. 37 to 1.73; I2
= 84%) and major bleeding (RR 1.13; 95% CI 0.39 to 3.31; I2 =
64%) (Hull 2006).
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Figure 7. Forest plot of comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist
(VKA), outcome: 1.7 Major bleeding.
Figure 8. Forest plot of comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist
(VKA), outcome: 1.7 Bleeding.
Thrombocytopenia
Two studies assessed thrombocytopenia as an outcome (Hull 2006;
Meyer 2002). The pooled analysis did not exclude a beneficial or
harmful effect of LMWH compared with VKA (RR 0.98; 95%CI
0.57 to 1.66; I2 = 0%) (Analysis 1.9). The results were consistent
in a sensitivity analysis excluding the study that used a different
initial anticoagulant in the two study arms (RR 0.89; 95%CI 0.49
to 1.60) (Hull 2006).
Postphlebitic syndrome
None of the studies reported postphlebitic syndrome as an out-
come.
Dabigatran versus warfarin
We obtained outcome data for the cancer subgroup directly from
the authors. The study by Schulman 2009 did not exclude a ben-
eficial or harmful effect with dabigatran compared with warfarin
with respect to mortality (RR 0.89; 95% CI 0.30 to 2.61), recur-
rent VTE (RR 0.59; 95% CI 0.10 to 3.43), major bleeding (RR
1.48; 95% CI 0.37 to 5.94), and thrombocytopenia (RR 6.25;
95% CI 0.33 to 118.38).
Extended ximelagatran versus no extended
ximelagatran
We obtained outcome data for the cancer subgroup directly from
the authors. Following initial anticoagulant treatment for six
months, 18 months’ extended treatment with ximelagatran 24 mg
twice daily did not exclude a beneficial or harmful effect for the
ourcomes of reduction in VTE (RR 0.47; 95% CI 0.04 to 4.94),
mortality (RR 1.41; 95%CI 0.25 to 7.91), or minor bleeding (RR
1.08; 95% CI 0.44 to 2.62) (Schulman 2003).
Idraparinux versus standard anticoagulation therapy
The study by vanDoormaal 2010 compared once-weekly subcuta-
neous injection of idraparinux for three or six months versus stan-
dard treatment (parenteral anticoagulation followed by warfarin
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or acenocoumarol). The reported findings suggested a reduction
in recurrent VTE (HR 0.39; 95% CI 0.14 to 1.11) at six months,
but did not exclude beneficial or harmful effects for the outcomes
of mortality (HR 0.99; 95% CI 0.66 to 1.48) and major bleeding
(RR 1.04 95% CI 0.39 to 2.83).
D I S C U S S I O N
Summary of main results
For the long-term treatment of VTE in patients with cancer,
LMWH compared with VKA provided no statistically significant
survival benefit but a statistically and patient important reduc-
tion in VTE. The findings did not exclude a beneficial or harm-
ful effect of LMWH compared with VKA in terms of bleeding
outcomes or thrombocytopenia. For dabigatran compared with
warfarin, a beneficial or harmful effect on mortality, major bleed-
ing, and thrombocytopenia could also not be excluded. Extended
treatment with ximelagatran following six months of anticoagu-
lant therapy could not be exclude a beneficial or harmful effect on
reduced VTE, mortality, and minor bleeding d. For once-weekly
subcutaneous injection of idraparinux compared with standard
treatment, the findings suggested a reduction in recurrent VTE,
but did not exclude beneficial or harmful effects for the outcomes
of mortality and bleeding.
Overall completeness and applicability of
evidence
While the reduction in venous thromboembolic events with
LMWH is expected to reduce thrombosis-related mortality, this
did not translate into an observed reduction in all-cause mortal-
ity. This finding is not apparently explained by an increase in any
specific-cause mortality (e.g. fatal bleeding), but might be due to
the lack of power to detect a reduction in all-cause mortality. Sim-
ilarly, the size of the available evidence was not large enough to
rule out beneficial or harmful effects for many comparisons (e.g.
effects of LMWH versus VKA on bleeding, effects of dabigatran
versus VKA on all outcomes).
We were unable to conduct subgroup analyses based on histologic
type or stage of cancer because of the lack of data. In the absence of
evidence for the contrary, we assume that the results of this study
apply to patients with any type or stage of cancer.
Quality of the evidence
For the comparison of LMWH versus VKA, the pooled results
for bleeding outcomes (LMWH versus VKA comparison) showed
moderate to severe heterogeneity. Unfortunately, the number of
pooled studies was relatively small to allow us to explore the causes
of heterogeneity by conducting subgroup analyses. We judged the
quality of evidence as low formortality,major bleeding, andminor
bleeding, and moderate for recurrent VTE (Summary of findings
for the main comparison).
Potential biases in the review process
Our systematic approach to searching, study selection, and data
extraction should have minimized the likelihood of missing rele-
vant studies. This increases the confidence in the internal valid-
ity of our findings. A major limitation of this review is that we
were unable to include in the meta-analyses 11 eligible RCTs with
subgroups of patients with cancer because relevant data were not
reported and not obtainable from the authors. However, the in-
verted funnel plot for the outcome of all-cause mortality did not
suggest publication bias. This suggests that the treatment effect
from those 11 RCTs should be similar to the one estimated from
the included studies. One has to keep in mind that funnel plots
have limited power to detect bias if the number of studies is small
(Higgins 2006).
Agreements and disagreements with other
studies or reviews
Of the three published systematic reviews comparing LMWH and
VKA in the long-term treatment of VTE (Conti 2003; Iorio 2003;
van der Heijden 2007), only the study by Iorio et al. conducted a
meta-analysis in the subgroup of patients with cancer and found
no statistically significant difference in mortality (OR 1.13; 95%
CI 0.54 to 2.38). This finding is consistent with the results of our
meta-analysis.
Two of the three systematic reviews showed no statistically signifi-
cant reduction of recurrent VTE by LMWH compared with VKA
when the meta-analysis was not restricted to patients with cancer
(Iorio 2003; van der Heijden 2007). However, our meta-analysis
showed a significant reduction in recurrent VTE in patients with
cancer. The reason for this possible differential effect in patients
with cancer is not clear.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The decision for a patient with cancer and venous thromboem-
bolism (VTE) to start long-term low molecular weight heparin
(LMWH) versus oral anticoagulation should balance the bene-
fits and harms and integrate the patient’s values and preferences
for outcomes and management options (Haynes 2002). While
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LMWH decreases the incidence of VTE and possibly of death, it
might be more costly and less acceptable because of its subcuta-
neous route of administration.
Implications for research
Future research should compare LMWH versus other anticoag-
ulants such as ximelagatran and fondaparinux. There is also a
need for research assessing patients’ values and preferences regard-
ing long-term anticoagulant agents for treating VTE. Researchers
should consider making the raw data from randomized controlled
trials (RCTs) available for individual patient data meta-analysis.
Further RCTs including subgroups of patients with cancer should
report separate results for these subgroups.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cesarone 2003
Methods Randomized trial
Participants 199 patients with cancer patients with DVT
17 drop-outs, 182 patients completed the study
Interventions Intervention: enoxaparin 100 IU/kg twice daily x 3 months
Control: coumadin (target INR 3) x 3 months
Outcomes Duration of follow-up: 3 months
• Mortality
• Major bleeding
• Recurrent DVT or PE but no data available
Diagnostic tests of DVT: ultrasound
Notes Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomised outpatient trial”
Allocation concealment (selection bias) Unclear risk Comment: not reported
Blinding of patients? Unclear risk Comment: not reported
Blinding of the providers? Unclear risk Comment: not reported
Blinding of the data collectors? Unclear risk Comment: not reported
Blinding of data analysis? Unclear risk Comment: not reported
Blinding of the outcome adjudicators? Unclear risk Comment: not reported
Incomplete data outcome reported? Low risk 91.5% follow-up
Free of selective reporting? High risk Abstract did not report bleeding events
Free of other bias? Low risk Study not reported as stopped early for benefit
Intention-to-treat analysis? Unclear risk Comment: not reported
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Deitcher 2006
Methods Randomized clinical trial
Participants 102 patients with active cancer with DVT, PE, or both;
85% Caucasian,
mean age 64 years, 46% male, previous VTE 8.7%
Interventions Intervention: enoxaparin 1 mg/kg twice daily x 5 days followed by 1.0-1.5 mg/kg daily
x 175 days (group 1a); enoxaparin 1.5 mg/kg daily x 175 days (group 1b)
Control: enoxaparin 1 mg/kg twice daily x 5 days followed by warfarin (target INR 2-
3) for a total of 180 days
Co-intervention: chemotherapy, radiation therapy, or both (not better specified)
Discontinued treatment: 52 of 102 patients overall
Outcomes Duration of follow-up: 1 year
• Mortality
• Symptomatic recurrent VTE
• Major bleeding
• Minor bleeding
No scheduled radiologic surveillance for VTE was conducted
Notes Funding: Aventis Pharmaceutical
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients were randomly allocated”
Allocation concealment (selection bias) High risk Quote: “This pilot feasibility study was conducted as a ran-
domised, open label….trial”
Blinding of patients? High risk Quote: “open label”
Comment: probably not
Blinding of the providers? High risk Quote: “open label”
Comment: probably not
Blinding of the data collectors? High risk Quote: “open label”
Comment: probably not
Blinding of data analysis? High risk Quote: “open label”
Comment: probably not
Blinding of the outcome adjudicators? High risk Quote: “open label”
Comment: probably not
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Deitcher 2006 (Continued)
Incomplete data outcome reported? Low risk % follow-up: from table 2, there were no participants lost
to follow-up
Free of selective reporting? Low risk Study not registered. No published protocol. All relevant
outcomes listed in the methods section were reported on
Comment: probably yes
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: probably yes
Intention-to-treat analysis? High risk Quote: “safety evaluations were performed on the safety
populations defined as all randomised patients who received
at least 1 dose of the study medication The intent to treat
population included all patient in safety population who
had at least 1 follow up measurement”
Quote: “of the 101 patients in the safety sample, 91 were
included in the intend to treat analysis”
Comment: definitely no
Hull 2006
Methods Randomized clinical trial
Participants 200 patients with cancer (solid or hematologic) with proximal DVT with or without PE
Minimum age 18 years; minimum life expectancy 3 months,
50% male,
19% had previous VTE
Interventions Interventions: tinzaparin 175 antiXa/kg SC daily for 12 weeks
Control: UFH either 5000 U or 80 U/kg for 5 days followed by VKA (target INR 2-3)
for 12 weeks
Outcomes Duration of follow-up: 12 months
• Recurrent VTE evaluated at 3 and 12 months
• Bleeding (major and minor) evaluated at 3 months
• Mortality at 3 and 12 months
Diagnostic test for recurrent VTE: venography or compression ultrasonography
Notes Funding: Canadian Institute for Health Research, industry grant, Leo Pharmaceutical,
Pharmion Pharmaceutical, and DuPont Pharmaceutical
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “a computer-derived randomised treatment sched-
ule was used; within the each stratum, the randomised
schedule was balanced in blocks of 2 and 4”
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Hull 2006 (Continued)
Allocation concealment (selection bias) High risk Quote: “multicenter, open-label randomised design”
Blinding of patients? High risk Quote: “open label clinical trial”
Quote: “A double-blind design was not feasible due to geo-
graphic location of many of the centres and necessarily large
number of primary care physicians providing anticoagulant
monitoring”
Comment: probably no
Blinding of the providers? High risk Quote: “open label clinical trial”
Quote: “A double-blind design was not feasible due to geo-
graphic location of many of the centres and necessarily large
number of primary care physicians providing anticoagulant
monitoring”
Comment: probably no
Blinding of the data collectors? High risk Quote: “open label clinical trial”
Quote: “A double-blind design was not feasible due to geo-
graphic location of many of the centres and necessarily large
number of primary care physicians providing anticoagulant
monitoring”
Comment: probably no
Blinding of data analysis? Low risk Quote: “open label clinical trial”
Quote: “A double-blind design was not feasible”
Comment: probably no
Blinding of the outcome adjudicators? High risk Quote: “Adjudication was made by 2 committee members
not involved in the patient’s care, and disputes were resolved
independently by a third. Members of the committee were
unaware of the patients’ treatment assignments”
Comment: probably yes
Incomplete data outcome reported? Low risk 99% follow-up
Free of selective reporting? Low risk Study not registered. No published protocol but a protocol
is clearly mentioned in the discussion. All relevant outcomes
listed in the methods section are reported on
Comment: probably yes
Free of other bias? Low risk Study not reported as stopped early for benefit
No other bias suspected
Comment: probably yes
Intention-to-treat analysis? Low risk Only 1% lost to follow-up and all patients randomized in-
cluded in the analyses of outcomes
Comment: probably yes
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Lee 2003
Methods Randomized clinical trial
Participants 676 patients with active cancer and with DVT, PE, or both; ECOG 1 or 2
Mean age 63 years, 49% male,11% history of DVT/PE
Interventions Intervention: dalteparin 200 IU/kg daily x 1 month followed by 150 IU/kg daily x 5
months
Control: dalteparin 200 IU/kg daily x 5-7 days followed by warfarin or acenocoumarol
(target INR 2-3) x 6 months; 46% of time on target
Outcomes Duration of follow-up: 6 months
• Symptomatic recurrent DVT and PE
• Clinically overt bleeding (both major bleeding and any bleeding)
• Mortality
Diagnostic tests for DVT: ultrasonography, venography
Diagnostic tests for PE: lung scan, angiography, autopsy
Notes Funding: Pharmacia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomizations was stratified according to the clin-
ical center and centralized at the coordinating and methods
center”
Allocation concealment (selection bias) High risk Quote: “the open label design could be a potential source
of bias”
Blinding of patients? High risk Quote: “we performed a multicenter, randomised, open la-
bel, clinical trial”
Quote: “we believed that a double blind design would not
logistically feasible or safe in patient with cancer”
Comment: probably no
Blinding of the providers? High risk Quote: “we performed a multicenter, randomised, open la-
bel, clinical trial”
Quote: “we believed that a double blind design would not
logistically feasible or safe in patient with cancer”
Comment: probably no
Blinding of the data collectors? Unclear risk Quote: “we performed a multicenter, randomised, open la-
bel, clinical trial”
Quote: “we believed that a double blind design would not
logistically feasible or safe in patient with cancer”
Comment: probably no
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Lee 2003 (Continued)
Blinding of data analysis? Low risk Quote: “a blinded reassessment of the sample size was spec-
ified in the protocol”
Comment: probably yes
Blinding of the outcome adjudicators? Low risk Quote: “all suspected events were reviewed by a central ad-
judication committee whose members were unaware of the
patient’s treatment assignments”
Comment: probably yes
Incomplete data outcome reported? Low risk 99% follow-up
Free of selective reporting? Low risk Study not registered. No published protocol. All relevant
outcomes listed in the methods section are reported on
Comment: probably yes
Free of other bias? Low risk Study not reported as stopped early for benefit.
no other bias suspected
Comment: probably yes
Intention-to-treat analysis? Low risk Quote: “an analysis of efficacy end points was performed ac-
cording to intention to treat principle and included all ran-
domised patients who had a confirmed, qualifying throm-
botic event and active cancer”
Comment: definitely yes
Lopez-Beret 2001
Methods Randomized clinical trial
Participants 35 patients with known malignancy; treated for symptomatic DVT of the lower limbs
Minimum age 18 years, mean age 65.7 years
Interventions Intervention: nadroparin 1.025 AXa IU/10 kg twice daily for 3 days then randomized
to nadroparin 1.025 antiXa IU/10 kg twice daily
Control: nadroparin 1.025 AXa IU/10 kg twice daily for 3 days then randomized to
acenocoumarol (target INR 2-3) for 3-6 months. After the 3rd month, nadroparin was
switched to once daily. 68% of INR values were on target
Outcomes Mortality DVT, PE, asymptomatic VTE, major bleeding, venous insufficiency
Duplex scan exam performed during routine vascular clinic visits at 1, 3, 6, and 12
months
Notes Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Lopez-Beret 2001 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “patients were allocated at random on third day to
receive a LMWH or an OA [oral anticoagulant]”
Allocation concealment (selection bias) Unclear risk Comment: not reported
Blinding of patients? High risk Quote: “in view of the nature of the treatments, it was not
possible to use a double design for the study”
Comment: probably no
Blinding of the providers? High risk Quote: “in view of the nature of the treatments, it was not
possible to use a double design for the study”
Comment: probably no
Blinding of the data collectors? High risk Quote: “in view of the nature of the treatments, it was not
possible to use a double design for the study”
Comment: probably no
Blinding of data analysis? Unclear risk Quote: “in view of the nature of the treatments, it was not
possible to use a double design for the study”
Comment: probably no
Blinding of the outcome adjudicators? Low risk Quote: “the final allocation of all potential outcome events,
including deaths, was made by an independent panel of
physicians”
Comment: probably yes
Incomplete data outcome reported? Low risk 100% follow-up
Free of selective reporting? Low risk Study not registered. No published protocol. All relevant
outcomes listed in the methods section are reported on
Comment: probably yes
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: probably yes
Intention-to-treat analysis? Low risk No loss to follow-up and all patients randomized included
in the analyses of outcomes
Meyer 2002
Methods Randomized clinical trial
Participants 146 patients with cancer (solid or hematologic; active or in remission but on treatment)
; with PE, DVT, or both
Minimum age 18 years; minimum life expectancy 3 months,
mean age 65.5 years, 45% male
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Meyer 2002 (Continued)
Interventions Intervention: enoxaparin 1.5 mg/kg daily x 3 month
Control: enoxaparin 1.5 mg/kg daily x 4 days followed by warfarin (target INR 2-3) x 3
months; 41% of time on target
The continuation and nature of anticoagulant treatment after 3 months were left to the
attending physician
Co-intervention: not reported
Outcomes Duration of follow-up: 3 and 6 months
• Asymptomatic VTE
• Symptomatic and objectively confirmed recurrent VTE
• Major bleeding
• Minor bleeding
• Thrombocytopenia
Screening tests for VTE: radiologic surveillance
Diagnostic tests for DVT: venography or compression ultrasonography
Diagnostic tests for PE: pulmonary angiography or ventilation perfusion scanning
Notes Funding: Aventis, Assistance Publique, Hospitaux de Paris
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Treatment allocation was balanced at each center
in blocks of 4”
Allocation concealment (selection bias) Low risk Quote: “randomisation was performed using pre sealed
treatment boxes”
Blinding of patients? High risk Quote: “this study was a multicenter, open label, ran-
domised trial”
Comment: probably no
Blinding of the providers? High risk Quote: “this study was a multicenter, open label, ran-
domised trial”
Comment: probably no
Blinding of the data collectors? High risk Quote: “this study was a multicenter, open label, ran-
domised trial”
Comment: probably no
Blinding of data analysis? High risk Quote: “this study was a multicenter, open label, ran-
domised trial”
Comment: probably no
Blinding of the outcome adjudicators? Low risk Quote: “all potential outcome events were assessed by an
independent adjudication committee whose members were
unaware of the treatment assignment”
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Meyer 2002 (Continued)
Comment: probably yes
Incomplete data outcome reported? Low risk 99% follow-up
Free of selective reporting? Low risk Study not registered. No published protocol. All relevant
outcomes listed in the methods section are reported on
Comment: probably yes
Free of other bias? Low risk Comment: study not reported as stopped early for benefit
Intention-to-treat analysis? Low risk Quote: “analysis was performed on an intention to treat
basis”
Romera 2009
Methods Randomized trial
Participants 69 patients with cancer (study subgroup) and symptomatic proximal DVT
Minimum age 18 years, mean age 61 years
Interventions Intervention: tinzaparin SC in a fixed dose of 175 IU anti-Xa per kg once daily for 6
months
Control: acenocoumarol 3 mg orally, which was subsequently adjusted to achieve an
INR of 2-3
All patients received tinzaparin SC in a fixed dose of 175 IU anti-Xa per kg once daily
Outcomes VTE (no data available for other outcomes in patients with cancer)
Scheduled radiologic surveillance for VTE was conducted at 1, 6, and 12 months after
entry
Screening testing for DVT: none
Diagnostic testing for DVT: duplex ultrasonography
Notes Funding: Hospital Universitari de Bellvitge, LEO Pharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients were randomised to either LMWH group SQ
[subcutaneous] or LMWH followed by acenocoumarol”
Allocation concealment (selection bias) High risk Quote: “A randomised, open-label trial”
Comment: not reported
Blinding of patients? High risk Quote: “we performed a randomised open label clinical trial”
Comment: probably no
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Romera 2009 (Continued)
Blinding of the providers? High risk Quote: “we performed a randomised open label clinical trial”
Comment: probably no
Blinding of the data collectors? Low risk Quote: “All objective diagnostic tests were interpreted by spe-
cialists who were not involved in the study”
Quote: “the ultrasonic evaluations were performed blindly”
Comment: probably yes
Blinding of data analysis? High risk Quote: “we performed a randomised open label clinical trial”
Comment: probably no
Blinding of the outcome adjudicators? Low risk Quote: “All objective diagnostic tests were interpreted by spe-
cialists who were not involved in the study”
Quote: “the ultrasonic evaluations were performed blindly”
Comment: probably yes
Incomplete data outcome reported? Low risk 100% follow-up
Free of selective reporting? Low risk Study is registered (NCT00689520). All relevant outcomes
listed on the registration page as well in the methods section of
the published manuscript are reported on
Comment: yes
Free of other bias? Low risk Study not reported as stopped early for benefit
No other bias suspected
Comment: probably yes
Intention-to-treat analysis? Low risk Quote: “Two patients (one from each group) who developed
symptoms of pulmonary embolism on the same day of randomi-
sation were also included in the analysis”
Comment: probably yes
Schulman 2003
Methods Double-blind randomized trial
Participants 66 patients with active cancer in the previous 5 years (study subgroup); treated for DVT
or PE for 6 months without recurrence
Minimum age 18 years, mean age 57 years
Interventions Intervention: initial anticoagulant treatment for 6 months; extended treatment with
ximelagatran 24 mg twice daily x 18 months
Control: initial anticoagulant treatment for 6 months; placebo x 18 months
Outcomes Duration of follow-up: 18 months
• Mortality
• Asymptomatic recurrent VTE (DVT and PE)
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Schulman 2003 (Continued)
• Major bleeding
• Minor bleeding (no data available for patients with cancer patients subgroup)
No scheduled radiologic surveillance for VTE was conducted
Notes Funding: AstraZeneca
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “use of a computer-generated randomizations
list”
Allocation concealment (selection bias) Low risk Quote: “the treatment group assignment was con-
cealed from all the investigators and their staff at the
coordinating center and the clinical centers and from
clinical monitors”
Blinding of patients? Low risk Quote: “multicenter, double blind, placebo-controlled
parallel group study”
Comment: probably yes
Blinding of the providers? Low risk Quote: “multicenter, double blind, placebo-controlled
parallel group study”
Comment: probably yes
Blinding of the data collectors? Low risk Quote: “multicenter, double blind, placebo-controlled
parallel group study”
Comment: probably yes
Blinding of data analysis? High risk Quote: “multicenter, double blind, placebo-controlled
parallel group study”
Comment: probably no
Blinding of the outcome adjudicators? Low risk Quote: “all suspected recurrent VTE events, includ-
ing those ruled out by local investigators, were adju-
dicated by a central, independent, blinded endpoint
committee”
Comment: definitely yes
Incomplete data outcome reported? Low risk 100% follow-up
Free of selective reporting? Low risk Study not registered. No published protocol. All rel-
evant outcomes listed in the methods section are re-
ported on
Comment: probably yes
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Schulman 2003 (Continued)
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: definitely yes
Intention-to-treat analysis? Low risk Quote: “All analyses presented are based on the treat-
ment period for the intention to treat population,
which was defined as all patients from whom any data
were available after randomizations, and who took at
least one dose of the study medication”
Quote: “Five patients in each group were excluded
from the intention-to-treat population since no data
were available for them after randomizations”
Comment: probably yes (10 out of 1233 represents
less than 1% of the study population)
Schulman 2009
Methods Randomized double-blind trial
Participants 121 patients with cancer (study subgroup) with DVT, PE, or both
Minimum age 18 years; mean age 60.5 years; 94.8% white people, 2.6% black people,
2.6% Asian people
Interventions Intervention: dabigatran 150 mg twice daily for 6 months
Control: warfarin adjusted to achieve an INR of 2-3 for 6 months
All patients were initially given parenteral anticoagulant therapy for a median of 9 days
Outcomes Mortality, symptomatic VTE, major bleeding, and minor bleeding at 6 months
No scheduled radiologic surveillance for VTE was conducted (no data available in the
paper, )
Notes Funding: Boehringer Ingelheim Pharmaceuticals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “we used a computer generated randomisation
scheme with variable block size stratified according to
the presentation”
Allocation concealment (selection bias) Low risk Quote: “the treatment group assignment were con-
cealed”
Blinding of patients? Low risk Quote: “double blind, double dummy randomised
trial”
Comment: probably yes
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Schulman 2009 (Continued)
Blinding of the providers? Low risk Quote: “double blind, double dummy randomised
trial”
Comment: probably yes
Blinding of the data collectors? Low risk Quote: “double blind, double dummy randomised
trial”
Comment: probably yes
Blinding of data analysis? Unclear risk Quote: “double blind, double dummy randomised
trial”
Comment: probably no
Blinding of the outcome adjudicators? Low risk Quote: “all suspected outcome event and deaths were
classified by central adjudication committees whose
members were unaware of the treatment assignments”
Comment: definitely yes
Incomplete data outcome reported? Low risk 99.7% follow-up
Free of selective reporting? Low risk Study is registered (NCT00291330). All relevant out-
comes listed on the registration page as well in the
methods section of the published manuscript are re-
ported on
Comment: definitely yes
Free of other bias? Low risk Study not reported as stopped early for benefit
Comment: definitely yes
Intention-to-treat analysis? Low risk Quote: “we analysed efficacy to a modified intention
to treat principle, since patients who did not receive
any study drug were excluded from all analyses as pre-
specified in the protocol”
Comment: probably yes
van Doormaal 2010
Methods Post hoc analysis in the subgroup of patients with cancer included in the Van GoghDVT
clinical trial (NCT00067093)
Participants 421 patients with a history or current cancer having acute symptomatic and objectively
confirmed DVT involving the popliteal, femoral, iliac veins, or the trifurcation of the
calf veins, without symptomatic PE
67% with active disease at entry, 53% male, mean age 67 years
Quote: “nodetailed informationon cancer type and stage or co-medicationwas collected”
Interventions Intervention: idraparinux 2.5 mg SC once-weekly x 3 or 6 months according to the
decision of the treating physician
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van Doormaal 2010 (Continued)
Control: standard treatment: tinzaparin, enoxaparin, or intravenous heparin adjusted
for the activated partial thromboplastin time ratio (ratio 1.5-2.5), followed by warfarin
or acenocoumarol (INR 2-3), which was started within 24 hours after randomization
Co-intervention: not reported
Quote: “A total of 8% of all patients were randomised in the 3-month arm, and 92% in
the 6-month treatment arm”
Quote: “The duration of treatmentwas similar with amedian of 183 days in both groups”
75% of participants completed the study medication
Quote: “Of idraparinux recipients 48 patients (22%) stopped the study medication
before the end of the study compared to 56 (28%) patients in the standard treatment
arm”
Outcomes Duration of follow-up: 6-month treatment period plus additional 3-month follow-up
period (median 183 days in both groups)
• Symptomatic objectively confirmed recurrent VTE: DVT (follow-up at 3 and 6
months ), non-fatal or fatal PE (follow-up at 6 and 9 months)
• Clinically relevant major bleeding (follow-up at 3 and 6 months)
• Clinically relevant non-major bleeding (follow-up at 3 and 6 months)
• All-cause mortality (follow-up at 6 and 9 months)
Screening testing for DVT/PE: none
Diagnostic testing for DVT/PE: none reported in this manuscript, but available from
Buller HR, New England Journal of Medicine 2007;357:1094-104. For diagnosis of re-
current PE: spiral computed tomography, pulmonary angiography. For diagnosis of re-
current DVT: ultrasonography, venography
Notes Quote: “This post-hoc analysis is under-powered to adequately test the hypothesis of
equivalence and should be considered as hypothesis generating”
Quote: “The data were gathered and maintained by the sponsor”
Note: Sanofi-Aventis France is idraparinux manufacturer
Quote: “The original trial was sponsored by Sanofi-Aventis. Their biostatisticians ex-
tracted the data of the present study”
Comment: probably not blinded
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “After giving written informed con-
sent, patients were randomly assigned to re-
ceive either idraparinux or standard ther-
apywith the use of a computerized voice-re-
sponse system” (from Buller HR, New Eng-
land Journal of Medicine 2007;357:1094-
104)
Allocation concealment (selection bias) Low risk Quote: “After giving written informed con-
sent, patients were randomly assigned to re-
ceive either idraparinux or standard ther-
apywith the use of a computerized voice-re-
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van Doormaal 2010 (Continued)
sponse system” (from Buller HR, New Eng-
land Journal of Medicine 2007;357:1094-
104)
Blinding of patients? High risk Open-label study
Comment: probably not blinded
Blinding of the providers? High risk Open-label study
Comment: probably not blinded
Blinding of the data collectors? High risk Open-label study
Comment: probably not blinded
Blinding of data analysis? High risk Open-label study
Comment: probably not blinded
Blinding of the outcome adjudicators? Low risk Quote: “All suspected outcomes were clas-
sified by an independent blinded adjudica-
tion committee”
Incomplete data outcome reported? Low risk Not reported
Comment: probably no loss to follow-up
Free of selective reporting? Low risk Post-hoc analysis. Study not registered. No
published protocol. All relevant outcomes
listed in the methods section are reported
on except for non-fatal PE
Comment: probably yes
Free of other bias? Low risk Study not reported as stopped early for ben-
efit
No other bias suspected
Comment: definitely yes
Intention-to-treat analysis? Low risk Quote: “The analyses were calculated in the
intention to treat population”
DVT: deep venous thrombosis; ECOG: Eastern Co-operative Oncology Group; INR: international normalized ratio; IU: international
units; PE: pulmonary embolism; SC: subcutaneous; U: unit; UFH: unfractionated heparin; VKA: vitamin K antagonist; VTE:
venous thromboembolism.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Altschuler 1990 Not an RCT (no control group)
Andrea 2003 Review
Astermark 1998 Observational study
Beckman 2003 Study included patients with cancer as a subgroup for which outcome data were not available
Bona 1997 Not an RCT (no control group)
Browse 1974 Review
Burgos 1999 No relevant outcome
Clarke-Pearson 1983 Retrospective study
Clenney 2003 Review
Das 1996 Study included patients with cancer as a subgroup for which outcome data were not available
Daskalopoulos 2005 Study included patients with cancer as a subgroup for which outcome data were not available
Eriksson 2005 Too few patients with cancer (1 in LMWH group)
Farred 2004 Not an RCT
Ferretti 2005 Review
Ferretti 2006 Review of another study
Fiessinger 2005 Study included patients with cancer as a subgroup for which outcome data were not available
Gonzalez-Fajardo 1999 Study included patients with cancer as a subgroup for which outcome data were not available
Hull 1996 Protocol
Hull 2000 Protocol
Hull 2007 Study included patients with cancer as a subgroup for which outcome data were not available
Hull 2009 Study included patients with cancer as a subgroup for which outcome data were not available
Hyers 2005 Review
Iorio 2003 Review
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Kakkar 2003 No patients with cancer
King 2005 Retrospective study
Kovacs 2005 Observational study
Kucher 2005 Study included patients with cancer as a subgroup for which outcome data were not available
Lee 2005 Review
Lee 2006 Review
Levine 1995 Study included patients with cancer as a subgroup for which outcome data were not available
Levine 2003 Review
Lopaciuk 1999 Study included patients with cancer as a subgroup for which outcome data were not available
Loprinzi 1999 No relevant outcome
Massicotte 2003 Study included patients with cancer as a subgroup for which outcome data were not available
McCan 2000 Review
Olin 1987 Retrospective study
Palareti 2000 Observational study
Partsch 2001 Observational study
Pinede 2001 No patients with cancer
Pini 1994 Study included patients with cancer as a subgroup for which outcome data were not available
Pérez-de-Llano 2010 Study included patients with cancer as a subgroup for which outcome data were not available
Schulman 2006 No patients with cancer
Schwartz 2005 Case series
Scott 2003 Review
Shattil 1984 Review
Siragusa 2010 Not intervention of interest: different duration of interventional drugs
Solymoss 1999 Review
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Stine 2004 Retrospective study
Streiff 2006 Review
Suarez Alvarez 2003 Not an RCT (no control group)
Taliani 2003 Observational study
Tedoldi 1993 No patients with cancer in study
Veiga 2000 Study included patients with cancer as a subgroup for which outcome data were not available
Vucic 2002 Observational study
LMWH: low molecular weight heparin; RCT: randomized controlled trial.
Characteristics of ongoing studies [ordered by study ID]
Kamphuisen 2010(Longheva)
Trial name or title Longheva
Methods Multicenter, multinational, randomized, open-label trial
Participants Participants with malignancy (all types, solid and hematologic) who have received 6-12 months of anticoag-
ulation for VTE and have an indication for continuing anticoagulation
Interventions Intervention: weight-adjusted scheme of LMWH for 6 additional months, 65-75% of full therapeutic dose
Control: vitamin K antagonists for 6 additional months
Outcomes Symptomatic recurrent VTE (DVT and PE)
All clinically relevant bleeding (i.e. major bleeding and other clinically relevant non-major bleeding)
All-cause mortality
Starting date August 2010
Contact information Prof. Pieter W. Kamphuisen, telephone: 0031503612943, email: p.w.kamphuisen@umcg.n
Notes Funding: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
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Lee 2013
Trial name or title CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute
venous thromboembolism in cancer patients. PROTOCOL
Methods Phase III, multinational, concealed, randomized, active-controlled, open-label trial with blinded adjudication
Participants Adults diagnosed with active cancer and a histologically or cytologically confirmed solid tumor or hematologic
malignancy
Interventions Intervention: tinzaparin 175 IU/kg once daily for 180 days (almost 6 months)
Control: warfarin once daily (target INR 2.0-3.0) overlapping with initial tinzaparin 175 IU/kg once daily
(5-10 days)
Outcomes Duration of follow-up: 1 month after last day of treatment (at 6 months)
• Symptomatic DVT
• Symptomatic non-fatal PE
• Fatal PE
• Incidental proximal DVT (popliteal vein or higher)
• Incidental proximal PE (segmental arteries or larger)
• Major bleeding
• Clinically relevant nonmajor bleeding
• All-cause mortality
• Heparin-induced thrombocytopenia
• Risk factors for recurrent VTE
• Post-thrombotic syndrome
• Health-related quality of life
• Healthcare resource utilization
Starting date August 2010
Contact information Email: Agnes.Lee@phsa.ca
Notes NCT01130025
Funding: LEO Pharma
Noble 2013 (ALICAT)
Trial name or title ALICAT
Methods Randomized, open-label, multicenter, mixed methods feasibility study
Participants Intervention: LMWH at treatment dose according to body weight for further 6 months
Control: no LMWH
Interventions Participants aged ≥ 16 years with locally advanced or metastatic cancer receiving LMWH for treatment of
catheter-associated thrombosis for 5 months
Outcomes Quality of life
Toxicities, including bleeding events and VTEs
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Noble 2013 (ALICAT) (Continued)
Starting date March 2013
Contact information Dr. Joanna D Smith, telephone: +44 (0)2920 687463, email: sealjd@cf.ac.uk
Notes Funding: Cardiff University
DVT: deep venous thrombosis; LMWH: low molecular weight heparin; PE: pulmonary embolism; VTE: venous thromboembolism.
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D A T A A N D A N A L Y S E S
Comparison 1. Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Survival (time-to-event) 3 1009 HR (Random, 95% CI) 0.96 [0.81, 1.14]
2 Mortality (at 3 months) 3 519 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.46, 1.28]
3 Mortality (at 6 months) 3 897 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.81, 1.13]
4 Mortality (at any time point) 6 1310 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.84, 1.11]
5 Recurrent venous
thromboembolism
(time-to-event)
3 1008 HR (Random, 95% CI) 0.47 [0.32, 0.71]
6 Recurrent venous
thromboembolism
5 1162 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.35, 0.71]
7 Major bleeding 4 1092 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.52, 2.19]
8 Minor bleeding 4 1091 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.51, 1.55]
9 Thrombocytopenia 2 341 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.57, 1.66]
Comparison 2. Dabigatran versus vitamin K antagonist
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 121 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.30, 2.61]
2 Recurrent venous
thromboembolism
1 121 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.10, 3.43]
3 Major bleeding 1 121 Risk Ratio (M-H, Random, 95% CI) 1.48 [0.37, 5.94]
4 Thrombocytopenia 1 121 Risk Ratio (M-H, Random, 95% CI) 6.25 [0.33, 118.38]
Comparison 3. Ximelagtran versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 66 Risk Ratio (M-H, Random, 95% CI) 1.41 [0.25, 7.91]
2 Minor bleeding 1 66 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.44, 2.62]
3 Recurrent venous
thromboembolism
1 66 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.04, 4.94]
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Analysis 1.1. Comparison 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA),
Outcome 1 Survival (time-to-event).
Review: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA)
Outcome: 1 Survival (time-to-event)
Study or subgroup LMWH VKA log [HR] HR Weight HR
N N (SE) IV,Random,95% CI IV,Random,95% CI
Hull 2006 100 99 -0.0429 (0.207) 17.1 % 0.96 [ 0.64, 1.44 ]
Lee 2003 336 336 -0.004 (0.1) 73.5 % 1.00 [ 0.82, 1.21 ]
Meyer 2002 67 71 -0.3285 (0.28) 9.4 % 0.72 [ 0.42, 1.25 ]
Total (95% CI) 503 506 100.0 % 0.96 [ 0.81, 1.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.19, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favors LMWH Favors VKA
Analysis 1.2. Comparison 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA),
Outcome 2 Mortality (at 3 months).
Review: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA)
Outcome: 2 Mortality (at 3 months)
Study or subgroup LMWH VKA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cesarone 2003 2/96 3/86 8.1 % 0.60 [ 0.10, 3.49 ]
Hull 2006 20/100 19/99 56.5 % 1.04 [ 0.59, 1.83 ]
Meyer 2002 8/67 17/71 35.4 % 0.50 [ 0.23, 1.08 ]
Total (95% CI) 263 256 100.0 % 0.77 [ 0.46, 1.28 ]
Total events: 30 (LMWH), 39 (VKA)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.40, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favors LMWH Favors VKA
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Analysis 1.3. Comparison 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA),
Outcome 3 Mortality (at 6 months).
Review: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA)
Outcome: 3 Mortality (at 6 months)
Study or subgroup LMWH VKA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Deitcher 2006 22/53 11/32 8.2 % 1.21 [ 0.68, 2.15 ]
Lee 2003 130/336 136/338 77.8 % 0.96 [ 0.80, 1.16 ]
Meyer 2002 22/67 29/71 13.9 % 0.80 [ 0.52, 1.25 ]
Total (95% CI) 456 441 100.0 % 0.96 [ 0.81, 1.13 ]
Total events: 174 (LMWH), 176 (VKA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favors LMWH Favors VKA
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Analysis 1.4. Comparison 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA),
Outcome 4 Mortality (at any time point).
Review: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA)
Outcome: 4 Mortality (at any time point)
Study or subgroup LMWH VKA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cesarone 2003 2/96 3/86 0.6 % 0.60 [ 0.10, 3.49 ]
Deitcher 2006 22/53 11/32 6.0 % 1.21 [ 0.68, 2.15 ]
Hull 2006 47/99 47/99 23.3 % 1.00 [ 0.75, 1.34 ]
Lee 2003 130/336 136/336 57.2 % 0.96 [ 0.79, 1.15 ]
Lopez-Beret 2001 7/17 6/18 2.7 % 1.24 [ 0.52, 2.94 ]
Meyer 2002 22/67 29/71 10.2 % 0.80 [ 0.52, 1.25 ]
Total (95% CI) 668 642 100.0 % 0.97 [ 0.84, 1.11 ]
Total events: 230 (LMWH), 232 (VKA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.90, df = 5 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA),
Outcome 5 Recurrent venous thromboembolism (time-to-event).
Review: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA)
Outcome: 5 Recurrent venous thromboembolism (time-to-event)
Study or subgroup LMWH VKA log [HR] HR Weight HR
N N (SE) IV,Random,95% CI IV,Random,95% CI
Hull 2006 99 99 -0.8819 (0.455) 20.6 % 0.41 [ 0.17, 1.01 ]
Lee 2003 336 336 -0.734 (0.24) 74.1 % 0.48 [ 0.30, 0.77 ]
Meyer 2002 67 71 -0.3567 (0.9) 5.3 % 0.70 [ 0.12, 4.08 ]
Total (95% CI) 502 506 100.0 % 0.47 [ 0.32, 0.71 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 3.60 (P = 0.00031)
Test for subgroup differences: Not applicable
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Favors LMWH Favors VKA
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Analysis 1.6. Comparison 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA),
Outcome 6 Recurrent venous thromboembolism.
Review: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA)
Outcome: 6 Recurrent venous thromboembolism
Study or subgroup LMWH VKA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Deitcher 2006 4/53 3/32 6.2 % 0.81 [ 0.19, 3.37 ]
Hull 2006 7/99 16/99 17.9 % 0.44 [ 0.19, 1.02 ]
Lee 2003 27/336 53/336 66.2 % 0.51 [ 0.33, 0.79 ]
Meyer 2002 2/67 3/71 4.1 % 0.71 [ 0.12, 4.10 ]
Romera 2009 2/36 7/33 5.7 % 0.26 [ 0.06, 1.17 ]
Total (95% CI) 591 571 100.0 % 0.50 [ 0.35, 0.71 ]
Total events: 42 (LMWH), 82 (VKA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.39, df = 4 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 3.84 (P = 0.00013)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favors LMWH Favors VKA
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Analysis 1.7. Comparison 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA),
Outcome 7 Major bleeding.
Review: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA)
Outcome: 7 Major bleeding
Study or subgroup LMWH VKA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Deitcher 2006 6/53 1/32 9.9 % 3.62 [ 0.46, 28.74 ]
Hull 2006 7/100 7/100 26.6 % 1.00 [ 0.36, 2.75 ]
Lee 2003 19/336 12/333 36.4 % 1.57 [ 0.77, 3.18 ]
Meyer 2002 5/67 12/71 27.2 % 0.44 [ 0.16, 1.19 ]
Total (95% CI) 556 536 100.0 % 1.07 [ 0.52, 2.19 ]
Total events: 37 (LMWH), 32 (VKA)
Heterogeneity: Tau2 = 0.24; Chi2 = 5.56, df = 3 (P = 0.14); I2 =46%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA),
Outcome 8 Minor bleeding.
Review: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA)
Outcome: 8 Minor bleeding
Study or subgroup LMWH VKA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Deitcher 2006 39/53 17/32 30.4 % 1.39 [ 0.96, 1.99 ]
Hull 2006 20/100 17/99 25.2 % 1.16 [ 0.65, 2.09 ]
Lee 2003 28/336 51/333 28.7 % 0.54 [ 0.35, 0.84 ]
Meyer 2002 5/67 9/71 15.7 % 0.59 [ 0.21, 1.67 ]
Total (95% CI) 556 535 100.0 % 0.89 [ 0.51, 1.55 ]
Total events: 92 (LMWH), 94 (VKA)
Heterogeneity: Tau2 = 0.23; Chi2 = 12.81, df = 3 (P = 0.01); I2 =77%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA),
Outcome 9 Thrombocytopenia.
Review: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA)
Outcome: 9 Thrombocytopenia
Study or subgroup LMWH VKA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hull 2006 6/100 4/99 18.5 % 1.49 [ 0.43, 5.10 ]
Meyer 2002 16/71 18/71 81.5 % 0.89 [ 0.49, 1.60 ]
Total (95% CI) 171 170 100.0 % 0.98 [ 0.57, 1.66 ]
Total events: 22 (LMWH), 22 (VKA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Dabigatran versus vitamin K antagonist, Outcome 1 Mortality.
Review: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Comparison: 2 Dabigatran versus vitamin K antagonist
Outcome: 1 Mortality
Study or subgroup Dabigatran Warfarin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Schulman 2009 6/64 6/57 100.0 % 0.89 [ 0.30, 2.61 ]
Total (95% CI) 64 57 100.0 % 0.89 [ 0.30, 2.61 ]
Total events: 6 (Dabigatran), 6 (Warfarin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
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Favors dabigatran Favors warfarin
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Analysis 2.2. Comparison 2 Dabigatran versus vitamin K antagonist, Outcome 2 Recurrent venous
thromboembolism.
Review: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Comparison: 2 Dabigatran versus vitamin K antagonist
Outcome: 2 Recurrent venous thromboembolism
Study or subgroup Dabigatran Warfarin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Schulman 2009 2/64 3/57 100.0 % 0.59 [ 0.10, 3.43 ]
Total (95% CI) 64 57 100.0 % 0.59 [ 0.10, 3.43 ]
Total events: 2 (Dabigatran), 3 (Warfarin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Favors dabigatran Favors warfarin
53Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.3. Comparison 2 Dabigatran versus vitamin K antagonist, Outcome 3 Major bleeding.
Review: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Comparison: 2 Dabigatran versus vitamin K antagonist
Outcome: 3 Major bleeding
Study or subgroup Dabigatran Warfarin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Schulman 2009 5/64 3/57 100.0 % 1.48 [ 0.37, 5.94 ]
Total (95% CI) 64 57 100.0 % 1.48 [ 0.37, 5.94 ]
Total events: 5 (Dabigatran), 3 (Warfarin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favors dabigatran Favors warfarin
Analysis 2.4. Comparison 2 Dabigatran versus vitamin K antagonist, Outcome 4 Thrombocytopenia.
Review: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Comparison: 2 Dabigatran versus vitamin K antagonist
Outcome: 4 Thrombocytopenia
Study or subgroup Dabigatran Warfarin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Schulman 2009 3/64 0/57 100.0 % 6.25 [ 0.33, 118.38 ]
Total (95% CI) 64 57 100.0 % 6.25 [ 0.33, 118.38 ]
Total events: 3 (Dabigatran), 0 (Warfarin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Ximelagtran versus placebo, Outcome 1 Mortality.
Review: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Comparison: 3 Ximelagtran versus placebo
Outcome: 1 Mortality
Study or subgroup Ximelagtran Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Schulman 2003 3/34 2/32 100.0 % 1.41 [ 0.25, 7.91 ]
Total (95% CI) 34 32 100.0 % 1.41 [ 0.25, 7.91 ]
Total events: 3 (Ximelagtran), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favors ximelagtran Favors placebo
Analysis 3.2. Comparison 3 Ximelagtran versus placebo, Outcome 2 Minor bleeding.
Review: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Comparison: 3 Ximelagtran versus placebo
Outcome: 2 Minor bleeding
Study or subgroup Ximelagtran Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Schulman 2003 8/34 7/32 100.0 % 1.08 [ 0.44, 2.62 ]
Total (95% CI) 34 32 100.0 % 1.08 [ 0.44, 2.62 ]
Total events: 8 (Ximelagtran), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Ximelagtran versus placebo, Outcome 3 Recurrent venous thromboembolism.
Review: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Comparison: 3 Ximelagtran versus placebo
Outcome: 3 Recurrent venous thromboembolism
Study or subgroup Ximelagtran Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Schulman 2003 1/34 2/32 100.0 % 0.47 [ 0.04, 4.94 ]
Total (95% CI) 34 32 100.0 % 0.47 [ 0.04, 4.94 ]
Total events: 1 (Ximelagtran), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favors ximelagtran Favors placebo
A D D I T I O N A L T A B L E S
Table 1. Glossary
Term Definition
Adjuvant therapy A therapy given in addition to the primary treatment to decrease the risk of the cancer recurrence
or to assist in the cure
Anticoagulation The process of hindering the clotting of blood especially by treatment with an anticoagulant
Antithrombotic Used against or tending to prevent thrombosis (clotting)
Coagulation Clotting
Deep vein thrombosis (DVT) A condition marked by the formation of a thrombus within a deep vein (as of the leg or pelvis) that
may be asymptomatic or be accompanied by symptoms (as swelling and pain) and that is potentially
life-threatening if dislodgment of the thrombus results in pulmonary embolism
Fondaparinux An anticoagulant medication
Hemostatic system The system that shortens the clotting time of blood and stops bleeding
Heparin An enzyme occurring especially in the liver and lungs that prolongs the clotting time of blood by
preventing the formation of fibrin. 2 forms of heparin that are used as anticoagulant medications
are: unfractionated heparin (UFH) and low molecular weight heparins (LMWH)
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Table 1. Glossary (Continued)
Impedance plethysmography A technique that measures the change in blood volume (venous blood volume as well as the pulsation
of the arteries) for a specific body segment
Kappa statistic A measure of degree of nonrandom agreement between observers, measurements of a specific cate-
gorical variable, or both
Metastasis The spread of a cancer cells from the initial or primary site of disease to another part of the body
Parenteral nutrition The practice of feeding a patient intravenously, circumventing the gastrointestinal tract
Pulmonary embolism (PE) Embolism of a pulmonary artery or one of its branches that is produced by foreign matter and most
often a blood clot originating in a vein of the leg or pelvis and that is marked by labored breathing,
chest pain, fainting, rapid heart rate, cyanosis, shock, and sometimes death
Thrombocytopenia Persistent decrease in the number of blood platelets that is often associated with hemorrhagic con-
ditions
Thrombosis The formation or presence of a blood clot within a blood vessel
Vitamin K antagonists Anticoagulant medications that are used for anticoagulation. Warfarin is a vitamin K antagonist
Warfarin An anticoagulant medication that is a vitamin K antagonist that is used for anticoagulation
Ximelagatran An anticoagulant medication
A P P E N D I C E S
Appendix 1. Full search strategies for the electronic databases
Database Strategy
Cochrane Central Register of Controlled Trials (CENTRAL) (lat-
est issue)
#1 heparin OR low molecular weight heparin OR LMWH OR
low-molecular-weight-heparinOR nadroparin OR fraxiparin OR
enoxaparin OR clexane OR lovenox OR dalteparin OR fragmin
OR ardeparin OR normiflo OR tinzaparin OR logiparin OR in-
nohep OR certoparin OR sandoparin OR reviparin OR clivarin
OR danaproid OR orgaran
#2 Coumarins OR Warfarin OR coumadin OR acenocumarol
OR phenprocumon OR 4-hydroxicoumarins OR oral anticoag-
ulant OR vitamin K antagonist OR VKA
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(Continued)
#3 fondaparinux OR Arixtra
#4 ximelagatran OR Exanta
#5 Pradaxa or Dabigatran or rivaroxaban or Xarelto or apixaban
#6 1 OR 2 OR 3 OR 4 OR 5
#7 malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR
adenocarcinoma OR tumour OR tumor
#8 6 AND 7
MEDLINE #1 Heparin/
#2 Heparin.tw
#3 Heparin, Low-Molecular-Weight/
#4 (LMWH OR low molecular weight heparin OR nadroparin
OR fraxiparin OR enoxaparin OR clexane OR lovenox OR dal-
teparin OR fragmin OR ardeparin OR normiflo OR tinzaparin
OR logiparin OR innohep OR certoparin OR sandoparin OR
reviparin OR clivarin OR danaproid OR orgaran).tw
#5 1 OR 2 OR 3 OR 4
#6 Coumarins/
#7 Warfarin/
#8 (warfarin OR coumadin OR acenocumarol OR phenprocu-
monOR 4-hydroxicoumarins OR oral anticoagulant OR vitamin
K antagonist OR VKA).tw
#9 6 OR 7 OR 8
#10 (fondaparinux OR Arixtra).tw
#11 (ximelagatran OR Exanta).tw
#12 (Pradaxa orDabigatran or rivaroxaban or Xarelto or apixaban)
.tw.
#13 5 OR 9 OR 10 OR 11 OR 12
#14 Neoplasms/
#15 (malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR
adenocarcinoma OR tumour OR tumor).tw
#16 14 OR 15
#17 clinical trial.pt. OR random:.tw. OR tu.xs.
#18 animals/ NOT human/
#19 17 NOT 18
#20 13 AND 16 AND 19
EMBASE #1 Heparin/
#2 heparin.tw
#3 Low Molecular Weight Heparin/
#4 (LMWH OR low molecular weight heparin OR nadroparin
OR fraxiparin OR enoxaparin OR clexane OR lovenox OR dal-
teparin OR fragmin OR ardeparin OR normiflo OR tinzaparin
OR logiparin OR innohep OR certoparin OR sandoparin OR
reviparin OR clivarin OR danaproid OR orgaran).tw
#5 1 OR 2 OR 3 OR 4
#6 Coumarin derivative/
#7 Warfarin/
#8 (warfarin OR coumadin OR acenocumarol OR phenprocu-
58Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
monOR 4-hydroxicoumarins OR oral anticoagulant OR vitamin
K antagonist OR VKA).tw
#9 6 OR 7 OR 8
#10 fondaparinux/
#11 (fondaparinux OR Arixtra).tw
#12 ximelagatran/
#13 (ximelagatran OR Exanta).tw
#14 (Pradaxa OR Dabigatran OR rivaroxaban OR Xarelto OR
apixaban).tw.
#15 5 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14
#16 Neoplasm/
#17 (malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR
adenocarcinoma OR tumour OR tumor).tw
#18 16 OR 17
#19Random:.tw.ORclinical trial:.mp.ORexphealth care quality
#20 animals/ NOT human/
#21 19 NOT 20
#22 15 AND 18 AND 21
ISI (International Scientific Information) the Web of Science #1 heparin OR low molecular weight heparin OR LMWH OR
low-molecular-weight-heparinOR nadroparin OR fraxiparin OR
enoxaparin OR clexane OR lovenox OR dalteparin OR fragmin
OR ardeparin OR normiflo OR tinzaparin OR logiparin OR in-
nohep OR certoparin OR sandoparin OR reviparin OR clivarin
OR danaproid OR orgaran
#2 Coumarins OR Warfarin OR coumadin OR acenocumarol
OR phenprocumon OR 4-hydroxicoumarins OR oral anticoag-
ulant OR vitamin K antagonist OR VKA
#3 fondaparinux OR Arixtra
#4 ximelagatran OR Exanta
#5 Pradaxa ORDabigatran OR rivaroxaban ORXareltoOR apix-
aban
#6 1 OR 2 OR 3 OR 4 OR 5
#7 malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR
adenocarcinoma OR tumour OR tumor
#8 random$ OR placebo$ OR versus OR vs OR double blind
OR double-blind OR compar$ OR controlled
#9 6 AND 7 AND 8
Appendix 2. Full search strategies for electronic databases - update 2013
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Database Strategy
CENTRAL (issue 12, 2012) #1 MeSH descriptor: [Heparin] explode all trees
#2 (LMWHor heparin or nadroparin or fraxiparin or enoxaparin or clexane or lovenox or dalteparin or
fragmin or ardeparin or normiflo or tinzaparin or logiparin or innohep or certoparin or sandoparin or
reviparin or clivarin or danaproid or orgaran or bemiparin or hibor, badyket, semuloparin, parnaparin,
fluxum)
#3 MeSH descriptor: [Coumarins] explode all trees
#4 (warfarin or coumadin or acenocumarol or phenprocumon or 4-hydroxicoumarins or oral antico-
agulant or vitamin K antagonist or VKA)
#5 (fondaparinux or arixtra)
#6 (ximelagatran or exanta)
#7 (pradaxa or dabigatran or rivaroxaban or xarelto or apixaban or eliquis or edoxaban or lixiana or
betrixaban or edoxaban or otamixaban)
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
#9 MeSH descriptor: [Neoplasms] explode all trees
#10 (malignan* or neoplasm* or cancer* or carcinoma* or adenocarcinoma* or tumour* or tumor*)
#11 #9 or #10
#12 #8 and #10
MEDLINE #1 exp Heparin/
#2 (LMWHor heparin or nadroparin or fraxiparin or enoxaparin or clexane or lovenox or dalteparin or
fragmin or ardeparin or normiflo or tinzaparin or logiparin or innohep or certoparin or sandoparin or
reviparin or clivarin or danaproid or orgaran or bemiparin or hibor, badyket, semuloparin, parnaparin,
fluxum).tw
#3 exp Coumarins/
#4 (warfarin or coumadin or acenocumarol or phenprocumon or 4-hydroxicoumarins or oral antico-
agulant or vitamin K antagonist or VKA).tw
#5 (fondaparinux or arixtra).tw.
#6 (ximelagatran or exanta).tw.
#7 (pradaxa or dabigatran or rivaroxaban or xarelto or apixaban or eliquis or edoxaban or lixiana or
betrixaban or edoxaban or otamixaban).tw
#8 1 or 2 or 3 or 4 or 5 or 6 or 7
#9 exp Neoplasms/
#10 (malignan* or neoplasm* or cancer* or carcinoma* or adenocarcinoma* or tumour* or tumor*).
tw
#11 9 or 10
#12 8 and 11
#13 randomised controlled trial.pt.
#14 controlled clinical trial.pt.
#15 randomized.ab.
#16 placebo.ab.
#17 drug therapy.fs.
#18 randomly.ab.
#19 trial.ab.
#20 groups.ab.
#21 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
#22 12 and 21
#23 exp animals/ not humans.sh.
#24 22 not 23
60Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
EMBASE #1 heparin/
#2 exp low molecular weight heparin/
#3 (LMWHor heparin or nadroparin or fraxiparin or enoxaparin or clexane or lovenox or dalteparin or
fragmin or ardeparin or normiflo or tinzaparin or logiparin or innohep or certoparin or sandoparin or
reviparin or clivarin or danaproid or orgaran or bemiparin or hibor, badyket, semuloparin, parnaparin,
fluxum).tw
#4 exp coumarin derivative/
#5 (warfarin or coumadin or acenocumarol or phenprocumon or 4-hydroxicoumarins or oral antico-
agulant or vitamin K antagonist or VKA).tw
#6 (fondaparinux or arixtra).tw.
#7 (ximelagatran or exanta).tw.
#8 (pradaxa or dabigatran or rivaroxaban or xarelto or apixaban or eliquis or edoxaban or lixiana or
betrixaban or edoxaban or otamixaban).tw
#9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
#10 exp neoplasm/
#11 (malignan* or neoplasm* or cancer* or carcinoma* or adenocarcinoma* or tumour* or tumor*).
tw
#12 10 or 11
#13 9 and 12
#14 crossover procedure/
#15 double-blind procedure/
#16 randomised controlled trial/
#17 single-blind procedure/
#18 random*.mp.
#19 factorial*.mp.
#20 (crossover* or cross over* or cross-over*).mp.
#21 placebo*.mp.
#22 (double* adj blind*).mp.
#23 (singl* adj blind*).mp.
#24 assign*.mp.
#25 allocat*.mp.
#26 volunteer*.mp.
#27 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
#28 13 and 27
#29 (exp animal/ or nonhuman/ or exp animal experiment/) not human/
#30 28 not 29
Appendix 3. Detailed statistical data abstraction
Outcome: Mortality at 3 months
Study
Name
LMWH UFH
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(Continued)
Events No
Rand
No most likely to
have MPD
No less
likely
to have
MPD[1]
No
with
avail-
able
out-
come
data
(for
CCA)
[2]
Events No
Rand
No more likely to
have MPD
No less
likely to
have
MPD
No.
with
avail-
able
out-
come
data
(for
CCA)
Pre-
trt[3]
Post-trt
[
Pre-trt Post-trt
Ce-
sarone
2003
2 96 0 0 0 96 3 86 0 0 0 86
Hull
2006
20 100 0 0 0 100 19 100 0 1 0 100-1=
99
Meyer
2002
8 71 0 4[5] 0 71-4=
67
17 75 0 4 0 75-4=
71
No: number; Rand: randomized; MPD: missing participant data; CCA: complete case analysis; Pre-trt: pre-treatment; Post-trt: post-
treatment; LMWH: low molecular weight heparin; UFH: unfractionated heparin.
[1]Participants reported as “non-compliant” (or “discontinued”) to treatment for various reasons excluding “loss to follow-up”, “with-
drawal of consent”, and “ineligible participants” (applies for both arms).
[2]Total number randomized - most likely MPD (pretreatment and post-treatment) (applies for both arms).
[3]Participants categorized as “ineligible” and did not receive first dose (applies for both arms).
[4]Participants categorized as “lost to follow-up”, “withdrew consent”, and “outcome not assessable” (applies for both arms).
[5] “8 (4 in each group) were considered not evaluable by the outcome adjudication committee” (Applies to both arms)
Outcome: Mortality at 6 months
Study
Name
LMWH UFH
Events No
Rand
No most likely to
have MPD
No less
likely
to have
MPD[1]
No
with
avail-
able
out-
come
data
(for
CCA)
Events No
Rand
No more likely to
have MPD
No less
likely to
have
MPD
No.
with
avail-
able
out-
come
data
(for
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(Continued)
[2] CCA)
Pre-
trt[3]
Post-trt
[4]
Pre-trt Post-trt
Deitcher
2006
22 32+36=
68
1+5+4=
10
3+2=5 10+19=
29
68-10-
5=53
11 34 0 2 16 34-2=
32
Lee A,
2003
130 338 0 2[5] 0 338-2=
336
136 338 0 2 0 338-2=
336
Meyer
2002
22 71 0 4[6] 0 71-4=
67
29 75 0 4 0 75-4=
71
Van
Door-
mal
2010
50 220 0 0 48 220 48 201 0 0 56 201
No: number; Rand: randomized; MPD: missing participant data; CCA: complete case analysis; Pre-trt: pre-treatment; Post-trt: post-
treatment; LMWH: low molecular weight heparin; UFH: unfractionated heparin.
[1]Participants reported as “non-compliant” (or “discontinued”) to treatment for various reasons excluding “loss to follow-up”, “with-
drawal of consent”, and “ineligible participants” (applies for both arms).
[2]Total number randomized - most likely MPD (pretreatment and post-treatment) (applies for both arms).
[3]Participants categorized as “ineligible” and did not receive first dose (applies for both arms).
[4]Participants categorized as “lost to follow-up”, “withdrew consent”, and “outcome not assessable” (applies for both arms).
[5]“Two patients in each group were excluded from the efficacy analysis because they did not have a qualifying thrombotic event: one
patient had a thrombosis in an arm vein, one had an asymptomatic thrombus in the leg, and the other two did not have a confirmed
pulmonary embolism”
[6 ]“8 (4 in each group) were considered not evaluable by the outcome adjudication committee” (Applies to both arms)
Outcome: Mortality at any point
Study
Name
LMWH UFH
Events No
Rand
No most likely to
have MPD
No less
likely
to have
MPD[1]
No
with
avail-
able
out-
come
data
(for
CCA)
[2]
Events No
Rand
No more likely to
have MPD
No less
likely to
have
MPD
No.
with
avail-
able
out-
come
data
(for
CCA)
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(Continued)
Pre-
trt[3]
Post-trt
[4]
Pre-trt Post-trt
Ce-
sarone
2003
2 96 0 0 0 96 3 86 0 0 0 86
Hull
2006
47 100 0 1 0 100-1=
99
47 100 0 1 0 100-1=
99
Van
Door-
mal
2010
50 220 0 0 48 220 48 201 0 0 56 201
Lee A,
2003
130 338 0 2[5] 0 338-2=
336
136 338 0 2 0 338-2=
336
Deitcher
2006
22 32+36=
68
1+5+4=
10
3+2=5 10+19=
29
68-10-
5=53
11 34 0 2 16 34-2=
32
Meyer
2002
22 71 0 4[6] 0 71-4=
67
29 75 0 4 0 75-4=
71
Lopez-
Beret
2001
7[7] 17 0 0 0 17 6 18 0 0 0 18
No: number; Rand: randomized; MPD: missing participant data; CCA: complete case analysis; Pre-trt: pre-treatment; Post-trt: post-
treatment; LMWH: low molecular weight heparin; UFH: unfractionated heparin.
[1]Participants reported as “non-compliant” (or “discontinued”) to treatment for various reasons excluding “loss to follow-up”, “with-
drawal of consent”, and “ineligible participants” (applies for both arms).
[2]Total number randomized - most likely MPD (pretreatment and post-treatment) (applies for both arms).
[3]Participants categorized as “ineligible” and did not receive first dose (applies for both arms).
[4]Participants categorized as “lost to follow-up”, “withdrew consent”, and “outcome not assessable” (applies for both arms).
[5]“Two patients in each group were excluded from the efficacy analysis because they did not have a qualifying thrombotic event: one
patient had a thrombosis in an arm vein, one had an asymptomatic thrombus in the leg, and the other two did not have a confirmed
pulmonary embolism”
[6] “8 (4 in each group) were considered not evaluable by the outcome adjudication committee” (Applies to both arms)
[7]“Thirteen patients with cancer at an advanced stage died because of the progression of their neoplastic disease: seven (41.2%) of 17
patients with malignancy in the LMWH group and six (33.3%) of 18 with cancer in the OA group.”
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Outcome: Recurrent VTE
Study
Name
LMWH UFH
Events No
Rand
No most likely to
have MPD
No less
likely
to have
MPD[1]
No
with
avail-
able
out-
come
data
(for
CCA)
[2]
Events No
Rand
No more likely to
have MPD
No less
likely to
have
MPD
No.
with
avail-
able
out-
come
data
(for
CCA)
Pre-
trt[3]
Post-trt
[4]
Pre-trt Post-trt
Romera
2009
2 36 0 0 0 36 7 33 0 0 0 33
Deitcher
2006
4 32+36=
68
1+5+4=
10
3+2=5 10+19=
29
68-10-
5=53
3 34 0 2 16 34-2=
32
Hull
2006
7 100 0 1 0 100-1=
99
16 100 0 1 0 100-1=
99
Van
Door-
maal
2010
5 220 0 0 48 220 12 201 0 0 56 201
Lee A,
2003
27 338 0 2[5] 0 338-2=
336
53 338 0 2 0 338-2=
336
Meyer
2002
2 71 0 4[6] 0 71-4=
67
3 75 0 4 0 75-4=
71
No: number; Rand: randomized; MPD: missing participant data; CCA: complete case analysis; Pre-trt: pre-treatment; Post-trt: post-
treatment; LMWH: low molecular weight heparin; UFH: unfractionated heparin.
[1]Participants reported as “non-compliant” (or “discontinued”) to treatment for various reasons excluding “loss to follow-up”, “with-
drawal of consent”, and “ineligible participants” (applies for both arms).
[2]Total number randomized - most likely MPD (pretreatment and post-treatment) (applies for both arms).
[3]Participants categorized as “ineligible” and did not receive first dose (applies for both arms).
[4]Participants categorized as “lost to follow-up”, “withdrew consent”, and “outcome not assessable” (applies for both arms).
[5]“Two patients in each group were excluded from the efficacy analysis because they did not have a qualifying thrombotic event: one
patient had a thrombosis in an arm vein, one had an asymptomatic thrombus in the leg, and the other two did not have a confirmed
pulmonary embolism”
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[6] “8 (4 in each group) were considered not evaluable by the outcome adjudication committee” (Applies to both arms)
Outcome: Major Bleeding
Study
Name
LMWH UFH
Events No
Rand
No most likely to
have MPD
No less
likely
to have
MPD[1]
No
with
avail-
able
out-
come
data
(for
CCA)
[2]
Events No
Rand
No more likely to
have MPD
No less
likely to
have
MPD
No.
with
avail-
able
out-
come
data
(for
CCA)
Pre-
trt[3]
Post-trt
[4]
Pre-trt Post-trt
Van
Door-
maal
2010
8 220 0 0 48 220 7 201 0 0 56 201
Deitcher
2006
6 32+36=
68
1+5+4=
10
3+2=5 10+19=
29
68-10-
5=53
1 34 0 2 16 34-2=
32
Hull
2006
7 100 0 0 0 100 7 100 0 1 0 100-1=
99
Lee A,
2003
19 338 0 2[5] 0 338-2=
336
12 338 3[6] 2 0 338-2-
3=333
Meyer
2002
5 71 0 4[7] 0 71-4=
67
12 75 0 4 0 75-4=
71
No: number; Rand: randomized; MPD: missing participant data; CCA: complete case analysis; Pre-trt: pre-treatment; Post-trt: post-
treatment; LMWH: low molecular weight heparin; UFH: unfractionated heparin.
[1]Participants reported as “non-compliant” (or “discontinued”) to treatment for various reasons excluding “loss to follow-up”, “with-
drawal of consent”, and “ineligible participants” (applies for both arms).
[2]Total number randomized - most likely MPD (pretreatment and post-treatment) (applies for both arms).
[3]Participants categorized as “ineligible” and did not receive first dose (applies for both arms).
[4]Participants categorized as “lost to follow-up”, “withdrew consent”, and “outcome not assessable” (applies for both arms).
[5]“Two patients in each group were excluded from the efficacy analysis because they did not have a qualifying thrombotic event: one
patient had a thrombosis in an arm vein, one had an asymptomatic thrombus in the leg, and the other two did not have a confirmed
pulmonary embolism”
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[6]“Three patients assigned to oral anticoagulant therapy did not receive the study drug and were excluded from the safety analyses.
Nineteen of 338 patients in the dalteparin group (6 percent) and 12 of 335 patients who received oral anticoagulant therapy (4 percent)
had major bleeding”
[7] “8 (4 in each group) were considered not evaluable by the outcome adjudication committee”(Applies to both arms)
Outcome: Minor Bleeding
Study
Name
LMWH UFH
Events No
Rand
No most likely to
have MPD
No less
likely
to have
MPD[1]
No
with
avail-
able
out-
come
data
(for
CCA)
[2]
Events No
Rand
No more likely to
have MPD
No less
likely to
have
MPD
No.
with
avail-
able
out-
come
data
(for
CCA)
Pre-
trt[3]
Post-trt
[4]
Pre-trt Post-trt
van
Door-
maal
2010
18 220 0 0 48 220 20 201 0 0 56 201
Deitcher
2006
39 32+36=
68
1+5+4=
10
3+2=5 10+19=
29
68-10-
5=53
17 34 0 2 16 34-2=
32
Hull
2006
20 100 0 0 0 100 17 100 0 1 0 100-1=
99
Meyer
2002
5 71 0 4[6] 0 71-4=
67
9 75 0 4 0 75-4=
71
Lee A,
2003
28[7] 338 0 2[8] 0 338-2=
336
51 338 3[9] 2 0 338-2-
3=333
No: number; Rand: randomized; MPD: missing participant data; CCA: complete case analysis; Pre-trt: pre-treatment; Post-trt: post-
treatment; LMWH: low molecular weight heparin; UFH: unfractionated heparin.
[1]Participants reported as “non-compliant” (or “discontinued”) to treatment for various reasons excluding “loss to follow-up”, “with-
drawal of consent”, and “ineligible participants” (applies for both arms).
[2]Total number randomized - most likely MPD (pretreatment and post-treatment) (applies for both arms).
[3]Participants categorized as “ineligible” and did not receive first dose (applies for both arms).
[4]Participants categorized as “lost to follow-up”, “withdrew consent”, and “outcome not assessable” (applies for both arms).
[5]Refers to both major and minor bleeding events. In this case I suggest not to report this outcome at 3 months.
[6]“8 (4 in each group) were considered not evaluable by the outcome adjudication committee” [6] (Applies to both arms)
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[7]“Nineteen of 338 patients in the dalteparin group (6 percent) and 12 of 335 patients who received oral anticoagulant therapy (4
percent) had major bleeding (P=0.27). The respective rates of any bleeding were 14 percent and 19 percent (P=0.09).”
[8]“Two patients in each group were excluded from the efficacy analysis because they did not have a qualifying thrombotic event: one
patient had a thrombosis in an arm vein, one had an asymptomatic thrombus in the leg, and the other two did not have a confirmed
pulmonary embolism”
[9]“Three patients assigned to oral anticoagulant therapy did not receive the study drug and were excluded from the safety analyses.
Nineteen of 338 patients in the dalteparin group (6 percent) and 12 of 335 patients who received oral anticoagulant therapy (4 percent)
had major bleeding”
Outcome: Thrombocytopenia
Study
Name
LMWH UFH
Events No
Rand
Nomost likely to
have MPD
No less
likely
to have
MPD[1]
No
with
avail-
able
out-
come
data
(for
CCA)
[2]
Events No
Rand
No more likely
to have MPD
No less
likely
to have
MPD
No.
with
avail-
able
out-
come
data
(for
CCA)
Pre-
trt[3]
Post-
trt [4]
Pre-trt Post-
trt
Hull
2006
6 100 0 0 0 100 4 100 0 1 0 100-
1=99
Meyer
2002
16 71 0 4[5] 0 71-4=
67
18 75 0 4 0 75-4=
71
No: number; Rand: randomized; MPD: missing participant data; CCA: complete case analysis; Pre-trt: pre-treatment; Post-trt: post-
treatment; LMWH: low molecular weight heparin; UFH: unfractionated heparin.
[1]Participants reported as “non-compliant” (or “discontinued”) to treatment for various reasons excluding “loss to follow-up”, “with-
drawal of consent”, and “ineligible participants” (applies for both arms).
[2]Total number randomized - most likely MPD (pretreatment and post-treatment) (applies for both arms).
[3]Participants categorized as “ineligible” and did not receive first dose (applies for both arms).
[4]Participants categorized as “lost to follow-up”, “withdrew consent”, and “outcome not assessable” (applies for both arms).
[5]“8 (4 in each group) were considered not evaluable by the outcome adjudication committee” [5] (Applies to both arms)
68Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
WH A T ’ S N E W
Date Event Description
11 February 2015 Amended Contact details updated.
H I S T O R Y
Protocol first published: Issue 3, 2007
Review first published: Issue 2, 2008
Date Event Description
25 June 2014 Amended Table format update
4 June 2014 New citation required but conclusions have not
changed
Data abstraction verified and detailed statistical data
included as appendix
Data reanalyzed by using a complete case analysis ap-
proach for the primary meta-analysis
9 February 2013 New search has been performed Search Updated
28 November 2012 Amended Author contact details amended
9 May 2011 New search has been performed Search updated 7 February 2010. One new RCT was
identified.
9 May 2011 New citation required but conclusions have not
changed
Onenew randomized controlled trial (RCT) identified
and added to review. New authors also added
C O N T R I B U T I O N S O F A U T H O R S
EAA: protocol development, search for trials, screening, data extraction, data analysis, manuscript drafting, review co-ordination.LK:
screening, data extraction, data analysis.MB: data extraction, data analysis.IN: screening.NL: data abstraction, manuscript drafting.SR:
screening, data extraction.IT: screening, data extraction.FS: screening, data extraction.PM: data analysis, methodologic advice.HJS:
protocol development, search for trials, data extraction, data analysis, methodologic advice.
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D E C L A R A T I O N S O F I N T E R E S T
HJS: no personal payments from for-profit sponsors related to the subject matter since 2010. EAA andHJS are members of the executive
committee of the American College of Chest Physicians’ Antithrombotic Therapy Guidelines.
S O U R C E S O F S U P P O R T
Internal sources
• State University of New York at Buffalo, Department of Medicine, USA.
• Italian National Cancer Institute Regina Elena Rome, Italy.
External sources
• No sources of support supplied
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Oral; Anticoagulants [adverse effects; ∗therapeutic use]; Azetidines [therapeutic use]; Benzimidazoles [therapeutic use];
Benzylamines [therapeutic use]; Dabigatran [therapeutic use]; Hemorrhage [chemically induced]; Heparin, Low-Molecular-Weight
[therapeutic use]; Neoplasms [∗complications]; Oligosaccharides [therapeutic use]; Randomized Controlled Trials as Topic; Venous
Thromboembolism [∗drug therapy; etiology; mortality]; Vitamin K [antagonists & inhibitors]; beta-Alanine [analogs & derivatives;
therapeutic use]
MeSH check words
Humans
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